risankizumab vs tildrakizumab

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: IL-23 p19 · full Psoriasis pipeline

risankizumab · Skyrizi

Marketed by AbbVie and partners

Approved in Psoriasismonoclonal antibody
Reliable signal

NCT02684370 · Phase 3 · completed

This randomized, triple-blind, placebo- and active-controlled trial used validated skin-clearance measures as its primary endpoints, and risankizumab achieved a highly statistically significant improvement over placebo on both: 75.3% vs 4.9% achieving PASI90, and 87.8% vs 7.8% achieving clear-or-almost-clear skin at Week 16.

Next expected readout: April 2028 · NCT04862286 (registry estimate)

Reported efficacy

Percentage of Participants Achieving 90% Improvement Psoriasis Area and Severity Index (PASI) Score (PASI90) From Baseline to Week 16 (Baseline, Week 16); Percentage of Participants Achieving Static Physician Global Assessment (sPGA) Score of Clear or Almost Clear at Week 16; Percentage of Participants Achieving sPGA Score of Clear or Almost Clear at Week 52: Co-primary endpoints at Week 16 (IMMhance study): PASI 90 73% risankizumab vs 2% placebo; sPGA 0/1 84% risankizumab vs 7% placebo; both p<0.001 (met)

Result source: NCT02672852

tildrakizumab · Ilumya

Marketed by Sun Pharmaceutical Industries and partners

Approved in Psoriasismonoclonal antibody
Reliable signal

NCT01729754 · Phase 3 · completed

This was a large, randomized, quadruple-blind, placebo- and active-controlled Phase 3 trial (N=1,090) in moderate-to-severe plaque psoriasis. The primary efficacy endpoints, PASI-75 and PGA clear/minimal at Week 12, were both statistically significant in favor of tildrakizumab 200 mg and 100 mg compared with placebo (p<0.001). The strong design and positive primary results provide high-quality evidence of treatment benefit.

Next expected readout: September 2028 · NCT05390515 (registry estimate)

Reported efficacy

Percentage of Participants With Psoriasis Area Sensitivity Index 75 (PASI-75) Response at Week 12 (Base Study) (Week 12 (or end of trial if prior to Week 12)); Percentage of Participants With a Physician's Global Assessment (PGA) Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline at Week 12 (Base Study) (Baseline and Week 12 (or end of trial if prior to Week 12)); Number of Participants Experiencing an Adverse Event Up to Week 12 (Base Study) (Up to 12 weeks); Number of Participants Discontinuing Study Drug Due to an Adverse Event Up to Week 12 (Base Study) (Up to 12 weeks); Number of Participants Discontinuing Study Drug Due to a Drug-Related Adverse Event (Base Study) (Up to 12 weeks): Percentage of Participants With Psoriasis Area Sensitivity Index 75 (PASI-75) Response at Week 12 (Base Study) (Week 12 (or end of trial if prior to Week 12)): Tildrakizumab 200 mg (Part 1) 62.3% | Tildrakizumab 100 mg (Part 1) 63.8% vs Placebo (Part 1) 5.8% (met)

Result source: NCT01722331

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointrisankizumabtildrakizumab
PASI 7585.2% vs 85.7%vs Ustekinumabwk 16 · n 54NCT04435600
19 other results
  • 83.3% vs 85.7% wk 16 · n 12 · Phase 3 · primary NCT04435600
  • 92.3% vs 85.7% wk 16 · n 13 · Phase 3 · primary NCT04435600
  • 86.7% vs 85.7% wk 16 · n 30 · Phase 3 · primary NCT04435600
  • 88.7% vs 8% wk 16 · n 407 · Phase 3 · secondary NCT02672852
  • 90.8% vs 6.1% wk 16 · n 294 · Phase 3 · secondary NCT02684357
  • 90.7% vs 71.7% wk 16 · n 301 · Phase 3 · secondary NCT02694523
  • 86.8% vs 70% wk 12 · n 304 · Phase 3 · secondary NCT02684370
  • 88.8% vs 69.7% wk 12 · n 294 · Phase 3 · secondary NCT02684357
  • 93.3% vs 26.7% wk 16 · n 60 · Phase 3 · secondary NCT03255382
  • 86.7% vs 20% wk 12 · n 60 · Phase 3 · secondary NCT03255382
  • 75% vs 8.3% wk 8 · n 60 · Phase 3 · secondary NCT03255382
  • 13.3% vs 3.3% wk 4 · n 60 · Phase 3 · secondary NCT03255382
  • 94.5% vs 8.6% 150 mg · wk 16 · n 55 · Phase 2 · secondary NCT03000075
  • 89.7% vs 8.6% 75 mg · wk 16 · n 58 · Phase 2 · secondary NCT03000075
  • 90.5% vs 77.5% 180 mg · wk 12 · n 42 · Phase 2 · secondary NCT02054481
  • 97.6% vs 77.5% 90 mg · wk 12 · n 41 · Phase 2 · secondary NCT02054481
  • 67.4% vs 77.5% 18 mg · wk 12 · n 43 · Phase 2 · secondary NCT02054481
  • 84.7% vs 18.8% wk 16 · n 118 · Phase 4 · secondary NCT04908475
  • 94% vs 77.5% 90+180 mg · wk 12 · n 83 · Phase 2 · secondary NCT02054481
66.3% vs 4.4%+61.9 vs placebo100 mg · wk 16 · n 89NCT01225731
31 other results
  • 74.4% vs 4.4% 200 mg · wk 16 · n 86 · Phase 2 · primary NCT01225731
  • 64.4% vs 4.4% 25 mg · wk 16 · n 90 · Phase 2 · primary NCT01225731
  • 33.3% vs 4.4% 5 mg · wk 16 · n 42 · Phase 2 · primary NCT01225731
  • 67.0% vs 4.9% 100 mg · wk 16 · n 89 · Phase 2 · secondary NCT01225731
  • 60.7% vs 4.4% 100 mg · wk 12 · n 89 · Phase 2 · secondary NCT01225731
  • 61.4% vs 4.8% 100 mg · wk 12 · n 89 · Phase 2 · secondary NCT01225731
  • 47.1% vs 4.7% 100 mg · wk 8 · n 89 · Phase 2 · secondary NCT01225731
  • 25% vs 2.3% 100 mg · wk 6 · n 89 · Phase 2 · secondary NCT01225731
  • 11.2% vs 0% 100 mg · wk 4 · n 89 · Phase 2 · secondary NCT01225731
  • 1.1% vs 0% 100 mg · wk 2 · n 89 · Phase 2 · secondary NCT01225731
  • 76.2% vs 4.9% 200 mg · wk 16 · n 86 · Phase 2 · secondary NCT01225731
  • 72.1% vs 4.4% 200 mg · wk 12 · n 86 · Phase 2 · secondary NCT01225731
  • 73.5% vs 4.8% 200 mg · wk 12 · n 86 · Phase 2 · secondary NCT01225731
  • 61.5% vs 4.7% 200 mg · wk 8 · n 86 · Phase 2 · secondary NCT01225731
  • 30.9% vs 2.3% 200 mg · wk 6 · n 86 · Phase 2 · secondary NCT01225731
  • 3.5% vs 0% 200 mg · wk 4 · n 86 · Phase 2 · secondary NCT01225731
  • 0% vs 0% 200 mg · wk 2 · n 86 · Phase 2 · secondary NCT01225731
  • 65.5% vs 4.9% 25 mg · wk 16 · n 90 · Phase 2 · secondary NCT01225731
  • 58.9% vs 4.4% 25 mg · wk 12 · n 90 · Phase 2 · secondary NCT01225731
  • 59.8% vs 4.8% 25 mg · wk 12 · n 90 · Phase 2 · secondary NCT01225731
  • 35.2% vs 4.7% 25 mg · wk 8 · n 90 · Phase 2 · secondary NCT01225731
  • 20.9% vs 2.3% 25 mg · wk 6 · n 90 · Phase 2 · secondary NCT01225731
  • 11.2% vs 0% 25 mg · wk 4 · n 90 · Phase 2 · secondary NCT01225731
  • 1.1% vs 0% 25 mg · wk 2 · n 90 · Phase 2 · secondary NCT01225731
  • 35% vs 4.9% 5 mg · wk 16 · n 42 · Phase 2 · secondary NCT01225731
  • 23.8% vs 4.4% 5 mg · wk 12 · n 42 · Phase 2 · secondary NCT01225731
  • 25% vs 4.8% 5 mg · wk 12 · n 42 · Phase 2 · secondary NCT01225731
  • 12.5% vs 4.7% 5 mg · wk 8 · n 42 · Phase 2 · secondary NCT01225731
  • 12.5% vs 2.3% 5 mg · wk 6 · n 42 · Phase 2 · secondary NCT01225731
  • 0% vs 0% 5 mg · wk 4 · n 42 · Phase 2 · secondary NCT01225731
  • 0% vs 0% 5 mg · wk 2 · n 42 · Phase 2 · secondary NCT01225731
PASI 9075.3% vs 4.9%+70.4 vs placebowk 16 · n 304NCT02684370
22 other results
  • 73.2% vs 2% wk 16 · n 407 · Phase 3 · primary NCT02672852
  • 74.8% vs 2% wk 16 · n 294 · Phase 3 · primary NCT02684357
  • 62.9% vs 3.8% wk 16 · n 105 · Phase 3 · primary NCT03875482
  • 72.4% vs 47.4% wk 16 · n 301 · Phase 3 · primary NCT02694523
  • 73.8% vs 65.6% wk 16 · n 164 · Phase 3 · primary NCT03478787
  • 75.3% vs 42% wk 16 · n 304 · Phase 3 · secondary NCT02684370
  • 74.8% vs 47.5% wk 16 · n 294 · Phase 3 · secondary NCT02684357
  • 64.8% vs 60.7% wk 16 · n 54 · Phase 3 · secondary NCT04435600
  • 76.7% vs 11.7% wk 16 · n 60 · Phase 3 · secondary NCT03255382
  • 61.7% vs 5% wk 12 · n 60 · Phase 3 · secondary NCT03255382
  • 38.3% vs 1.7% wk 8 · n 60 · Phase 3 · secondary NCT03255382
  • 1.7% vs 0% wk 4 · n 60 · Phase 3 · secondary NCT03255382
  • 83.3% vs 60.7% wk 16 · n 12 · Phase 3 · secondary NCT04435600
  • 84.6% vs 60.7% wk 16 · n 13 · Phase 3 · secondary NCT04435600
  • 76.7% vs 60.7% wk 16 · n 30 · Phase 3 · secondary NCT04435600
  • 74.5% vs 1.7% 150 mg · wk 16 · n 55 · Phase 2 · primary NCT03000075
  • 75.9% vs 1.7% 75 mg · wk 16 · n 58 · Phase 2 · primary NCT03000075
  • 81% vs 40% 180 mg · wk 12 · n 42 · Phase 2 · primary NCT02054481
  • 73.2% vs 40% 90 mg · wk 12 · n 41 · Phase 2 · primary NCT02054481
  • 32.6% vs 40% 18 mg · wk 12 · n 43 · Phase 2 · primary NCT02054481
  • 55.9% vs 5.1% wk 16 · n 118 · Phase 4 · primary NCT04908475
  • 77.1% vs 40% 90+180 mg · wk 12 · n 83 · Phase 2 · primary NCT02054481
38.6% vs 2.4%+36.2 vs placebo100 mg · wk 16 · n 88NCT01225731
3 other results
  • 52.4% vs 2.4% 200 mg · wk 16 · n 84 · Phase 2 · secondary NCT01225731
  • 25.3% vs 2.4% 25 mg · wk 16 · n 87 · Phase 2 · secondary NCT01225731
  • 12.5% vs 2.4% 5 mg · wk 16 · n 40 · Phase 2 · secondary NCT01225731
PASI 10035.9% vs 0%+35.9 vs placebowk 16 · n 304NCT02684370
20 other results
  • 47.2% vs 1% wk 16 · n 407 · Phase 3 · secondary NCT02672852
  • 50.7% vs 2% wk 16 · n 294 · Phase 3 · secondary NCT02684357
  • 38.1% vs 1.9% wk 16 · n 105 · Phase 3 · secondary NCT03875482
  • 35.9% vs 12% wk 16 · n 304 · Phase 3 · secondary NCT02684370
  • 50.7% vs 24.2% wk 16 · n 294 · Phase 3 · secondary NCT02684357
  • 39.9% vs 23% wk 16 · n 301 · Phase 3 · secondary NCT02694523
  • 40.7% vs 17.9% wk 16 · n 54 · Phase 3 · secondary NCT04435600
  • 35% vs 1.7% wk 16 · n 60 · Phase 3 · secondary NCT03255382
  • 23.3% vs 1.7% wk 12 · n 60 · Phase 3 · secondary NCT03255382
  • 5% vs 1.7% wk 8 · n 60 · Phase 3 · secondary NCT03255382
  • 0% vs 0% wk 4 · n 60 · Phase 3 · secondary NCT03255382
  • 41.7% vs 17.9% wk 16 · n 12 · Phase 3 · secondary NCT04435600
  • 53.8% vs 17.9% wk 16 · n 13 · Phase 3 · secondary NCT04435600
  • 43.3% vs 17.9% wk 16 · n 30 · Phase 3 · secondary NCT04435600
  • 32.7% vs 0% 150 mg · wk 16 · n 55 · Phase 2 · secondary NCT03000075
  • 22.4% vs 0% 75 mg · wk 16 · n 58 · Phase 2 · secondary NCT03000075
  • 50% vs 17.5% 180 mg · wk 12 · n 42 · Phase 2 · secondary NCT02054481
  • 41.5% vs 17.5% 90 mg · wk 12 · n 41 · Phase 2 · secondary NCT02054481
  • 14% vs 17.5% 18 mg · wk 12 · n 43 · Phase 2 · secondary NCT02054481
  • 45.8% vs 17.5% 90+180 mg · wk 12 · n 83 · Phase 2 · secondary NCT02054481
14.8% vs 0%+14.8 vs placebo100 mg · wk 16 · n 88NCT01225731
3 other results
  • 16.7% vs 0% 200 mg · wk 16 · n 84 · Phase 2 · secondary NCT01225731
  • 9.2% vs 0% 25 mg · wk 16 · n 87 · Phase 2 · secondary NCT01225731
  • 5% vs 0% 5 mg · wk 16 · n 40 · Phase 2 · secondary NCT01225731
sPGA 0/187.8% vs 7.8%+80 vs placebowk 16 · n 304NCT02684370
28 other results
  • 83.5% vs 7% wk 16 · n 407 · Phase 3 · primary NCT02672852
  • 83.7% vs 5.1% wk 16 · n 294 · Phase 3 · primary NCT02684357
  • 78.1% vs 9.6% wk 16 · n 105 · Phase 3 · primary NCT03875482
  • 83.7% vs 60.2% wk 16 · n 301 · Phase 3 · primary NCT02694523
  • 79.6% vs 75% wk 16 · n 54 · Phase 3 · primary NCT04435600
  • 68.5% vs 67.9% wk 16 · n 54 · Phase 3 · primary NCT04435600
  • 83.3% vs 75% wk 16 · n 12 · Phase 3 · primary NCT04435600
  • 84.6% vs 75% wk 16 · n 13 · Phase 3 · primary NCT04435600
  • 90% vs 75% wk 16 · n 30 · Phase 3 · primary NCT04435600
  • 83.3% vs 67.9% wk 16 · n 12 · Phase 3 · primary NCT04435600
  • 84.6% vs 67.9% wk 16 · n 13 · Phase 3 · primary NCT04435600
  • 83.3% vs 67.9% wk 16 · n 30 · Phase 3 · primary NCT04435600
  • 32.2% vs 11.5% wk 16 · n 87 · Phase 3 · secondary NCT04713592
  • 87.8% vs 63% wk 16 · n 304 · Phase 3 · secondary NCT02684370
  • 83.7% vs 61.6% wk 16 · n 294 · Phase 3 · secondary NCT02684357
  • 82.2% vs 65% wk 12 · n 304 · Phase 3 · secondary NCT02684370
  • 82.3% vs 64.6% wk 12 · n 294 · Phase 3 · secondary NCT02684357
  • 91.7% vs 31.7% wk 16 · n 60 · Phase 3 · secondary NCT03255382
  • 90% vs 33.3% wk 12 · n 60 · Phase 3 · secondary NCT03255382
  • 81.7% vs 15% wk 8 · n 60 · Phase 3 · secondary NCT03255382
  • 33.3% vs 3.3% wk 4 · n 60 · Phase 3 · secondary NCT03255382
  • 75.4% vs 18.4% wk 16 · n 118 · Phase 4 · primary NCT04908475
  • 92.7% vs 10.3% 150 mg · wk 16 · n 55 · Phase 2 · secondary NCT03000075
  • 86.2% vs 10.3% 75 mg · wk 16 · n 58 · Phase 2 · secondary NCT03000075
  • 90.5% vs 67.5% 180 mg · wk 12 · n 42 · Phase 2 · secondary NCT02054481
  • 90.2% vs 67.5% 90 mg · wk 12 · n 41 · Phase 2 · secondary NCT02054481
  • 62.8% vs 67.5% 18 mg · wk 12 · n 43 · Phase 2 · secondary NCT02054481
  • 90.4% vs 67.5% 90+180 mg · wk 12 · n 83 · Phase 2 · secondary NCT02054481
61.8% vs 2.2%+59.6 vs placebo100 mg · wk 16 · n 89NCT01225731
3 other results
  • 74.4% vs 2.2% 200 mg · wk 16 · n 86 · Phase 2 · secondary NCT01225731
  • 57.8% vs 2.2% 25 mg · wk 16 · n 90 · Phase 2 · secondary NCT01225731
  • 33.3% vs 2.2% 5 mg · wk 16 · n 42 · Phase 2 · secondary NCT01225731
DLQI, change-17 vs -9.7vs Fumadermwk 16 · n 59NCT03255382-8.5 vs 1−9.5 vs placebo100 mg · wk 16 · n 88NCT01225731
3 other results
  • -8.8 vs 1 200 mg · wk 16 · n 83 · Phase 2 · secondary NCT01225731
  • -9.2 vs 1 25 mg · wk 16 · n 87 · Phase 2 · secondary NCT01225731
  • -4.9 vs 1 5 mg · wk 16 · n 40 · Phase 2 · secondary NCT01225731

PASI 75

risankizumab
85.2% vs 85.7%vs Ustekinumabwk 16 · n 54NCT04435600
19 other results
  • 83.3% vs 85.7% wk 16 · n 12 · Phase 3 · primary NCT04435600
  • 92.3% vs 85.7% wk 16 · n 13 · Phase 3 · primary NCT04435600
  • 86.7% vs 85.7% wk 16 · n 30 · Phase 3 · primary NCT04435600
  • 88.7% vs 8% wk 16 · n 407 · Phase 3 · secondary NCT02672852
  • 90.8% vs 6.1% wk 16 · n 294 · Phase 3 · secondary NCT02684357
  • 90.7% vs 71.7% wk 16 · n 301 · Phase 3 · secondary NCT02694523
  • 86.8% vs 70% wk 12 · n 304 · Phase 3 · secondary NCT02684370
  • 88.8% vs 69.7% wk 12 · n 294 · Phase 3 · secondary NCT02684357
  • 93.3% vs 26.7% wk 16 · n 60 · Phase 3 · secondary NCT03255382
  • 86.7% vs 20% wk 12 · n 60 · Phase 3 · secondary NCT03255382
  • 75% vs 8.3% wk 8 · n 60 · Phase 3 · secondary NCT03255382
  • 13.3% vs 3.3% wk 4 · n 60 · Phase 3 · secondary NCT03255382
  • 94.5% vs 8.6% 150 mg · wk 16 · n 55 · Phase 2 · secondary NCT03000075
  • 89.7% vs 8.6% 75 mg · wk 16 · n 58 · Phase 2 · secondary NCT03000075
  • 90.5% vs 77.5% 180 mg · wk 12 · n 42 · Phase 2 · secondary NCT02054481
  • 97.6% vs 77.5% 90 mg · wk 12 · n 41 · Phase 2 · secondary NCT02054481
  • 67.4% vs 77.5% 18 mg · wk 12 · n 43 · Phase 2 · secondary NCT02054481
  • 84.7% vs 18.8% wk 16 · n 118 · Phase 4 · secondary NCT04908475
  • 94% vs 77.5% 90+180 mg · wk 12 · n 83 · Phase 2 · secondary NCT02054481
tildrakizumab
66.3% vs 4.4%+61.9 vs placebo100 mg · wk 16 · n 89NCT01225731
31 other results
  • 74.4% vs 4.4% 200 mg · wk 16 · n 86 · Phase 2 · primary NCT01225731
  • 64.4% vs 4.4% 25 mg · wk 16 · n 90 · Phase 2 · primary NCT01225731
  • 33.3% vs 4.4% 5 mg · wk 16 · n 42 · Phase 2 · primary NCT01225731
  • 67.0% vs 4.9% 100 mg · wk 16 · n 89 · Phase 2 · secondary NCT01225731
  • 60.7% vs 4.4% 100 mg · wk 12 · n 89 · Phase 2 · secondary NCT01225731
  • 61.4% vs 4.8% 100 mg · wk 12 · n 89 · Phase 2 · secondary NCT01225731
  • 47.1% vs 4.7% 100 mg · wk 8 · n 89 · Phase 2 · secondary NCT01225731
  • 25% vs 2.3% 100 mg · wk 6 · n 89 · Phase 2 · secondary NCT01225731
  • 11.2% vs 0% 100 mg · wk 4 · n 89 · Phase 2 · secondary NCT01225731
  • 1.1% vs 0% 100 mg · wk 2 · n 89 · Phase 2 · secondary NCT01225731
  • 76.2% vs 4.9% 200 mg · wk 16 · n 86 · Phase 2 · secondary NCT01225731
  • 72.1% vs 4.4% 200 mg · wk 12 · n 86 · Phase 2 · secondary NCT01225731
  • 73.5% vs 4.8% 200 mg · wk 12 · n 86 · Phase 2 · secondary NCT01225731
  • 61.5% vs 4.7% 200 mg · wk 8 · n 86 · Phase 2 · secondary NCT01225731
  • 30.9% vs 2.3% 200 mg · wk 6 · n 86 · Phase 2 · secondary NCT01225731
  • 3.5% vs 0% 200 mg · wk 4 · n 86 · Phase 2 · secondary NCT01225731
  • 0% vs 0% 200 mg · wk 2 · n 86 · Phase 2 · secondary NCT01225731
  • 65.5% vs 4.9% 25 mg · wk 16 · n 90 · Phase 2 · secondary NCT01225731
  • 58.9% vs 4.4% 25 mg · wk 12 · n 90 · Phase 2 · secondary NCT01225731
  • 59.8% vs 4.8% 25 mg · wk 12 · n 90 · Phase 2 · secondary NCT01225731
  • 35.2% vs 4.7% 25 mg · wk 8 · n 90 · Phase 2 · secondary NCT01225731
  • 20.9% vs 2.3% 25 mg · wk 6 · n 90 · Phase 2 · secondary NCT01225731
  • 11.2% vs 0% 25 mg · wk 4 · n 90 · Phase 2 · secondary NCT01225731
  • 1.1% vs 0% 25 mg · wk 2 · n 90 · Phase 2 · secondary NCT01225731
  • 35% vs 4.9% 5 mg · wk 16 · n 42 · Phase 2 · secondary NCT01225731
  • 23.8% vs 4.4% 5 mg · wk 12 · n 42 · Phase 2 · secondary NCT01225731
  • 25% vs 4.8% 5 mg · wk 12 · n 42 · Phase 2 · secondary NCT01225731
  • 12.5% vs 4.7% 5 mg · wk 8 · n 42 · Phase 2 · secondary NCT01225731
  • 12.5% vs 2.3% 5 mg · wk 6 · n 42 · Phase 2 · secondary NCT01225731
  • 0% vs 0% 5 mg · wk 4 · n 42 · Phase 2 · secondary NCT01225731
  • 0% vs 0% 5 mg · wk 2 · n 42 · Phase 2 · secondary NCT01225731

PASI 90

risankizumab
75.3% vs 4.9%+70.4 vs placebowk 16 · n 304NCT02684370
22 other results
  • 73.2% vs 2% wk 16 · n 407 · Phase 3 · primary NCT02672852
  • 74.8% vs 2% wk 16 · n 294 · Phase 3 · primary NCT02684357
  • 62.9% vs 3.8% wk 16 · n 105 · Phase 3 · primary NCT03875482
  • 72.4% vs 47.4% wk 16 · n 301 · Phase 3 · primary NCT02694523
  • 73.8% vs 65.6% wk 16 · n 164 · Phase 3 · primary NCT03478787
  • 75.3% vs 42% wk 16 · n 304 · Phase 3 · secondary NCT02684370
  • 74.8% vs 47.5% wk 16 · n 294 · Phase 3 · secondary NCT02684357
  • 64.8% vs 60.7% wk 16 · n 54 · Phase 3 · secondary NCT04435600
  • 76.7% vs 11.7% wk 16 · n 60 · Phase 3 · secondary NCT03255382
  • 61.7% vs 5% wk 12 · n 60 · Phase 3 · secondary NCT03255382
  • 38.3% vs 1.7% wk 8 · n 60 · Phase 3 · secondary NCT03255382
  • 1.7% vs 0% wk 4 · n 60 · Phase 3 · secondary NCT03255382
  • 83.3% vs 60.7% wk 16 · n 12 · Phase 3 · secondary NCT04435600
  • 84.6% vs 60.7% wk 16 · n 13 · Phase 3 · secondary NCT04435600
  • 76.7% vs 60.7% wk 16 · n 30 · Phase 3 · secondary NCT04435600
  • 74.5% vs 1.7% 150 mg · wk 16 · n 55 · Phase 2 · primary NCT03000075
  • 75.9% vs 1.7% 75 mg · wk 16 · n 58 · Phase 2 · primary NCT03000075
  • 81% vs 40% 180 mg · wk 12 · n 42 · Phase 2 · primary NCT02054481
  • 73.2% vs 40% 90 mg · wk 12 · n 41 · Phase 2 · primary NCT02054481
  • 32.6% vs 40% 18 mg · wk 12 · n 43 · Phase 2 · primary NCT02054481
  • 55.9% vs 5.1% wk 16 · n 118 · Phase 4 · primary NCT04908475
  • 77.1% vs 40% 90+180 mg · wk 12 · n 83 · Phase 2 · primary NCT02054481
tildrakizumab
38.6% vs 2.4%+36.2 vs placebo100 mg · wk 16 · n 88NCT01225731
3 other results
  • 52.4% vs 2.4% 200 mg · wk 16 · n 84 · Phase 2 · secondary NCT01225731
  • 25.3% vs 2.4% 25 mg · wk 16 · n 87 · Phase 2 · secondary NCT01225731
  • 12.5% vs 2.4% 5 mg · wk 16 · n 40 · Phase 2 · secondary NCT01225731

PASI 100

risankizumab
35.9% vs 0%+35.9 vs placebowk 16 · n 304NCT02684370
20 other results
  • 47.2% vs 1% wk 16 · n 407 · Phase 3 · secondary NCT02672852
  • 50.7% vs 2% wk 16 · n 294 · Phase 3 · secondary NCT02684357
  • 38.1% vs 1.9% wk 16 · n 105 · Phase 3 · secondary NCT03875482
  • 35.9% vs 12% wk 16 · n 304 · Phase 3 · secondary NCT02684370
  • 50.7% vs 24.2% wk 16 · n 294 · Phase 3 · secondary NCT02684357
  • 39.9% vs 23% wk 16 · n 301 · Phase 3 · secondary NCT02694523
  • 40.7% vs 17.9% wk 16 · n 54 · Phase 3 · secondary NCT04435600
  • 35% vs 1.7% wk 16 · n 60 · Phase 3 · secondary NCT03255382
  • 23.3% vs 1.7% wk 12 · n 60 · Phase 3 · secondary NCT03255382
  • 5% vs 1.7% wk 8 · n 60 · Phase 3 · secondary NCT03255382
  • 0% vs 0% wk 4 · n 60 · Phase 3 · secondary NCT03255382
  • 41.7% vs 17.9% wk 16 · n 12 · Phase 3 · secondary NCT04435600
  • 53.8% vs 17.9% wk 16 · n 13 · Phase 3 · secondary NCT04435600
  • 43.3% vs 17.9% wk 16 · n 30 · Phase 3 · secondary NCT04435600
  • 32.7% vs 0% 150 mg · wk 16 · n 55 · Phase 2 · secondary NCT03000075
  • 22.4% vs 0% 75 mg · wk 16 · n 58 · Phase 2 · secondary NCT03000075
  • 50% vs 17.5% 180 mg · wk 12 · n 42 · Phase 2 · secondary NCT02054481
  • 41.5% vs 17.5% 90 mg · wk 12 · n 41 · Phase 2 · secondary NCT02054481
  • 14% vs 17.5% 18 mg · wk 12 · n 43 · Phase 2 · secondary NCT02054481
  • 45.8% vs 17.5% 90+180 mg · wk 12 · n 83 · Phase 2 · secondary NCT02054481
tildrakizumab
14.8% vs 0%+14.8 vs placebo100 mg · wk 16 · n 88NCT01225731
3 other results
  • 16.7% vs 0% 200 mg · wk 16 · n 84 · Phase 2 · secondary NCT01225731
  • 9.2% vs 0% 25 mg · wk 16 · n 87 · Phase 2 · secondary NCT01225731
  • 5% vs 0% 5 mg · wk 16 · n 40 · Phase 2 · secondary NCT01225731

sPGA 0/1

risankizumab
87.8% vs 7.8%+80 vs placebowk 16 · n 304NCT02684370
28 other results
  • 83.5% vs 7% wk 16 · n 407 · Phase 3 · primary NCT02672852
  • 83.7% vs 5.1% wk 16 · n 294 · Phase 3 · primary NCT02684357
  • 78.1% vs 9.6% wk 16 · n 105 · Phase 3 · primary NCT03875482
  • 83.7% vs 60.2% wk 16 · n 301 · Phase 3 · primary NCT02694523
  • 79.6% vs 75% wk 16 · n 54 · Phase 3 · primary NCT04435600
  • 68.5% vs 67.9% wk 16 · n 54 · Phase 3 · primary NCT04435600
  • 83.3% vs 75% wk 16 · n 12 · Phase 3 · primary NCT04435600
  • 84.6% vs 75% wk 16 · n 13 · Phase 3 · primary NCT04435600
  • 90% vs 75% wk 16 · n 30 · Phase 3 · primary NCT04435600
  • 83.3% vs 67.9% wk 16 · n 12 · Phase 3 · primary NCT04435600
  • 84.6% vs 67.9% wk 16 · n 13 · Phase 3 · primary NCT04435600
  • 83.3% vs 67.9% wk 16 · n 30 · Phase 3 · primary NCT04435600
  • 32.2% vs 11.5% wk 16 · n 87 · Phase 3 · secondary NCT04713592
  • 87.8% vs 63% wk 16 · n 304 · Phase 3 · secondary NCT02684370
  • 83.7% vs 61.6% wk 16 · n 294 · Phase 3 · secondary NCT02684357
  • 82.2% vs 65% wk 12 · n 304 · Phase 3 · secondary NCT02684370
  • 82.3% vs 64.6% wk 12 · n 294 · Phase 3 · secondary NCT02684357
  • 91.7% vs 31.7% wk 16 · n 60 · Phase 3 · secondary NCT03255382
  • 90% vs 33.3% wk 12 · n 60 · Phase 3 · secondary NCT03255382
  • 81.7% vs 15% wk 8 · n 60 · Phase 3 · secondary NCT03255382
  • 33.3% vs 3.3% wk 4 · n 60 · Phase 3 · secondary NCT03255382
  • 75.4% vs 18.4% wk 16 · n 118 · Phase 4 · primary NCT04908475
  • 92.7% vs 10.3% 150 mg · wk 16 · n 55 · Phase 2 · secondary NCT03000075
  • 86.2% vs 10.3% 75 mg · wk 16 · n 58 · Phase 2 · secondary NCT03000075
  • 90.5% vs 67.5% 180 mg · wk 12 · n 42 · Phase 2 · secondary NCT02054481
  • 90.2% vs 67.5% 90 mg · wk 12 · n 41 · Phase 2 · secondary NCT02054481
  • 62.8% vs 67.5% 18 mg · wk 12 · n 43 · Phase 2 · secondary NCT02054481
  • 90.4% vs 67.5% 90+180 mg · wk 12 · n 83 · Phase 2 · secondary NCT02054481
tildrakizumab
61.8% vs 2.2%+59.6 vs placebo100 mg · wk 16 · n 89NCT01225731
3 other results
  • 74.4% vs 2.2% 200 mg · wk 16 · n 86 · Phase 2 · secondary NCT01225731
  • 57.8% vs 2.2% 25 mg · wk 16 · n 90 · Phase 2 · secondary NCT01225731
  • 33.3% vs 2.2% 5 mg · wk 16 · n 42 · Phase 2 · secondary NCT01225731

DLQI, change

risankizumab
-17 vs -9.7vs Fumadermwk 16 · n 59NCT03255382
tildrakizumab
-8.5 vs 1−9.5 vs placebo100 mg · wk 16 · n 88NCT01225731
3 other results
  • -8.8 vs 1 200 mg · wk 16 · n 83 · Phase 2 · secondary NCT01225731
  • -9.2 vs 1 25 mg · wk 16 · n 87 · Phase 2 · secondary NCT01225731
  • -4.9 vs 1 5 mg · wk 16 · n 40 · Phase 2 · secondary NCT01225731
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
4 other shared endpoints and safety

Coverage. risankizumab: 8 of 8 rows · tildrakizumab: 8 of 8 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricrisankizumab
Rows use multiple source trials
tildrakizumab
Rows use multiple source trials
DLQI 0/1
responder rate · % of participants
No placebo or comparator arm
47.1% (n=244) @ 52wk*a,b,c
NCT04102007 · Phase 3 · registry result, not featured evidence · converted to % from 115 Participants as posted
56.3% (n=55) @ 52wk100 mga,b,c
NCT03718299 · Phase 4 · registry result, not featured evidence
Itch NRS
absolute change · score
No placebo or comparator arm
-2.8 score @ 16wka,b,c
NCT04435600 · Phase 3
-3.8 score @ 16wk100 mga,b,c
NCT03718299 · Phase 4 · registry result, not featured evidence
PASI
absolute change · score
Induction
-16.89 vs -9.11 Fumaderm score @ 16wkd,b,c
NCT03255382 · Phase 3 · registry result, not featured evidence
-14.9 vs -2.4 placebo score @ 16wk100 mge,d,b,c
NCT01225731 · Phase 2 · registry result, not featured evidence
show 3 more doses
-15.6 vs -2.4 placebo score @ 16wk200 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
-14.6 vs -2.4 placebo score @ 16wk25 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
-10 vs -2.4 placebo score @ 16wk5 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
PASI 50
responder rate · % of participants
Induction
91.7% (n=12) vs 92.9% (n=28) Ustekinumab @ 16wke,d,b,c
NCT04435600 · Phase 3
show 3 more doses
90.7% (n=54) vs 92.9% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
100% (n=13) vs 92.9% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
96.7% (n=30) vs 92.9% (n=28) Ustekinumab @ 16wk
NCT04435600 · Phase 3
82.02% (n=89) vs 8.89% (n=45) placebo @ 16wk100 mge,d,b,c
NCT01225731 · Phase 2 · registry result, not featured evidence
show 3 more doses
91.86% (n=86) vs 8.89% (n=45) placebo @ 16wk200 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
82.22% (n=90) vs 8.89% (n=45) placebo @ 16wk25 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
57.14% (n=42) vs 8.89% (n=45) placebo @ 16wk5 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
Dropout rate
1.6%Risankizumab (Part A)f
NCT02684370 · Phase 3
show 53 more results
—Risankizumab/Risankizumab (Part B)
NCT02684370 · Phase 3
1%Risankizumab (Part A1)
NCT02672852 · Phase 3
—Risankizumab/Risankizumab (Part B;
NCT02672852 · Phase 3
0%Part 1: Risankizumab
NCT04435600 · Phase 3
—Part 2 Period A Risankizumab Non-r
NCT04435600 · Phase 3
—Part 2 Period A Risankizumab Respo
NCT04435600 · Phase 3
—Part 2 Period A: Risankizumab
NCT04435600 · Phase 3
—Part 2 Period C: Risankizumab
NCT04435600 · Phase 3
—Part 3: Risankizumab
NCT04435600 · Phase 3
—Part 4: Risankizumab
NCT04435600 · Phase 3
0.7%Risankizumab (Part A)
NCT02684357 · Phase 3
—Risankizumab/Risankizumab (Part B)
NCT02684357 · Phase 3
—Adalimumab/Rerandomized to Risanki
NCT02694523 · Phase 3
—Adalimumab/Risankizumab (Part B)
NCT02694523 · Phase 3
2.3%Risankizumab (Part A)
NCT02694523 · Phase 3
—Risankizumab/Risankizumab (Part B)
NCT02694523 · Phase 3
1.8%Study-G Risankizumab (Period A)
NCT05969223 · Phase 4
—Study-G Risankizumab/Risankizumab
NCT05969223 · Phase 4
0%Study-S Risankizumab (Period A)
NCT05969223 · Phase 4
—Study-S Risankizumab/Risankizumab
NCT05969223 · Phase 4
—Period A: RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: APR/APR/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: APR/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: APR/RZB, NR
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: RZB/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
26.2%150 mg
NCT03047395 · Phase 3 · registry result, not featured evidence
3.4%Risankizumab
NCT04713592 · Phase 3 · registry result, not featured evidence
—Risankizumab (Double-blind Period)
NCT04713592 · Phase 3 · registry result, not featured evidence
—Risankizumab/Risankizumab
NCT04713592 · Phase 3 · registry result, not featured evidence
—Risankizumab/Risankizumab (Open-la
NCT04713592 · Phase 3 · registry result, not featured evidence
16%
NCT04102007 · Phase 3 · registry result, not featured evidence
—150 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
—150 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
—75 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
—75 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
11.1%
NCT03875508 · Phase 3 · registry result, not featured evidence
12.4%
NCT03875482 · Phase 3 · registry result, not featured evidence
7.9%
NCT03478787 · Phase 3 · registry result, not featured evidence
0%
NCT03255382 · Phase 3 · registry result, not featured evidence
70%600 mg
NCT05283135 · Phase 2 · registry result, not featured evidence
70%300 mg
NCT05283135 · Phase 2 · registry result, not featured evidence
—180 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
—90 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
0%150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
—75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
0%75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
—75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
4.8%180 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
4.9%90 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
9.3%18 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
—100 mgf
NCT01729754 · Phase 3 · monotherapy
show 24 more results
—200 mg
NCT01729754 · Phase 3 · monotherapy
—100 mg
NCT01722331 · Phase 3 · monotherapy
—100 mg
NCT01722331 · Phase 3 · monotherapy
—100 mg
NCT01722331 · Phase 3 · monotherapy
—200 mg
NCT01722331 · Phase 3 · monotherapy
—200 mg
NCT01722331 · Phase 3 · monotherapy
—200 mg
NCT01722331 · Phase 3 · monotherapy
15.7%100 mg
NCT03897075 · Phase 3
—100 mg
NCT03897075 · Phase 3
16.7%
NCT04271540 · Phase 4 · registry result, not featured evidence
0%
NCT04541329 · Phase 4 · registry result, not featured evidence
18.2%100 mg
NCT03718299 · Phase 4 · registry result, not featured evidence
1.1%100 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—100 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—100 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
2.3%200 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—200 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—200 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
5.4%25 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—25 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—25 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
4.8%5 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—5 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—5 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
0.3%Risankizumab (Part A)f
NCT02684370 · Phase 3
show 53 more results
—Risankizumab/Risankizumab (Part B)
NCT02684370 · Phase 3
0.2%Risankizumab (Part A1)
NCT02672852 · Phase 3
—Risankizumab/Risankizumab (Part B;
NCT02672852 · Phase 3
—Part 1: Risankizumab
NCT04435600 · Phase 3
—Part 2 Period A Risankizumab Non-r
NCT04435600 · Phase 3
—Part 2 Period A Risankizumab Respo
NCT04435600 · Phase 3
—Part 2 Period A: Risankizumab
NCT04435600 · Phase 3
—Part 2 Period C: Risankizumab
NCT04435600 · Phase 3
—Part 3: Risankizumab
NCT04435600 · Phase 3
—Part 4: Risankizumab
NCT04435600 · Phase 3
0%Risankizumab (Part A)
NCT02684357 · Phase 3
—Risankizumab/Risankizumab (Part B)
NCT02684357 · Phase 3
—Adalimumab/Rerandomized to Risanki
NCT02694523 · Phase 3
—Adalimumab/Risankizumab (Part B)
NCT02694523 · Phase 3
1%Risankizumab (Part A)
NCT02694523 · Phase 3
—Risankizumab/Risankizumab (Part B)
NCT02694523 · Phase 3
—Study-G Risankizumab (Period A)
NCT05969223 · Phase 4
—Study-G Risankizumab/Risankizumab
NCT05969223 · Phase 4
—Study-S Risankizumab (Period A)
NCT05969223 · Phase 4
—Study-S Risankizumab/Risankizumab
NCT05969223 · Phase 4
—Period A: RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: APR/APR/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: APR/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: APR/RZB, NR
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: RZB/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
6.5%150 mg
NCT03047395 · Phase 3 · registry result, not featured evidence
1.1%Risankizumab
NCT04713592 · Phase 3 · registry result, not featured evidence
—Risankizumab (Double-blind Period)
NCT04713592 · Phase 3 · registry result, not featured evidence
—Risankizumab/Risankizumab
NCT04713592 · Phase 3 · registry result, not featured evidence
—Risankizumab/Risankizumab (Open-la
NCT04713592 · Phase 3 · registry result, not featured evidence
1.6%
NCT04102007 · Phase 3 · registry result, not featured evidence
—150 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
—150 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
—75 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
—75 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
0.9%
NCT03875508 · Phase 3 · registry result, not featured evidence
0%
NCT03875482 · Phase 3 · registry result, not featured evidence
0.6%
NCT03478787 · Phase 3 · registry result, not featured evidence
0%
NCT03255382 · Phase 3 · registry result, not featured evidence
—600 mg
NCT05283135 · Phase 2 · registry result, not featured evidence
—300 mg
NCT05283135 · Phase 2 · registry result, not featured evidence
—180 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
—90 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
0%150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
—75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
0%75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
—75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
0%180 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
2.4%90 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
2.3%18 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
—100 mgf
NCT01729754 · Phase 3 · monotherapy
show 24 more results
—200 mg
NCT01729754 · Phase 3 · monotherapy
—100 mg
NCT01722331 · Phase 3 · monotherapy
—100 mg
NCT01722331 · Phase 3 · monotherapy
—100 mg
NCT01722331 · Phase 3 · monotherapy
—200 mg
NCT01722331 · Phase 3 · monotherapy
—200 mg
NCT01722331 · Phase 3 · monotherapy
—200 mg
NCT01722331 · Phase 3 · monotherapy
—100 mg
NCT03897075 · Phase 3
—100 mg
NCT03897075 · Phase 3
—
NCT04271540 · Phase 4 · registry result, not featured evidence
—
NCT04541329 · Phase 4 · registry result, not featured evidence
1.8%100 mg
NCT03718299 · Phase 4 · registry result, not featured evidence
1.1%100 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—100 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—100 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
1.2%200 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—200 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—200 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
2.2%25 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—25 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—25 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
2.4%5 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—5 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
—5 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
Serious AEs
2.3%Risankizumab (Part A)f
NCT02684370 · Phase 3
show 53 more results
5.4%Risankizumab/Risankizumab (Part B)
NCT02684370 · Phase 3
2%Risankizumab (Part A1)
NCT02672852 · Phase 3
11.7%Risankizumab/Risankizumab (Part B;
NCT02672852 · Phase 3
0%Part 1: Risankizumab
NCT04435600 · Phase 3
10%Part 2 Period A Risankizumab Non-r
NCT04435600 · Phase 3
0%Part 2 Period A Risankizumab Respo
NCT04435600 · Phase 3
0%Part 2 Period A: Risankizumab
NCT04435600 · Phase 3
0%Part 2 Period C: Risankizumab
NCT04435600 · Phase 3
0%Part 3: Risankizumab
NCT04435600 · Phase 3
0%Part 4: Risankizumab
NCT04435600 · Phase 3
2%Risankizumab (Part A)
NCT02684357 · Phase 3
4.5%Risankizumab/Risankizumab (Part B)
NCT02684357 · Phase 3
5.7%Adalimumab/Rerandomized to Risanki
NCT02694523 · Phase 3
10.5%Adalimumab/Risankizumab (Part B)
NCT02694523 · Phase 3
3.3%Risankizumab (Part A)
NCT02694523 · Phase 3
4.1%Risankizumab/Risankizumab (Part B)
NCT02694523 · Phase 3
1.8%Study-G Risankizumab (Period A)
NCT05969223 · Phase 4
1.9%Study-G Risankizumab/Risankizumab
NCT05969223 · Phase 4
5.9%Study-S Risankizumab (Period A)
NCT05969223 · Phase 4
5.9%Study-S Risankizumab/Risankizumab
NCT05969223 · Phase 4
0.8%Period A: RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
0%Period B: APR/APR/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
2.9%Period B: APR/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: APR/RZB, NR
NCT04908475 · Phase 4 · registry result, not featured evidence
6.9%Period B: RZB/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
20%150 mg
NCT03047395 · Phase 3 · registry result, not featured evidence
—Risankizumab
NCT04713592 · Phase 3 · registry result, not featured evidence
5.7%Risankizumab (Double-blind Period)
NCT04713592 · Phase 3 · registry result, not featured evidence
—Risankizumab/Risankizumab
NCT04713592 · Phase 3 · registry result, not featured evidence
6%Risankizumab/Risankizumab (Open-la
NCT04713592 · Phase 3 · registry result, not featured evidence
7%
NCT04102007 · Phase 3 · registry result, not featured evidence
25%150 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
50%150 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
20%75 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
0%75 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
5.6%
NCT03875508 · Phase 3 · registry result, not featured evidence
1%
NCT03875482 · Phase 3 · registry result, not featured evidence
5.5%
NCT03478787 · Phase 3 · registry result, not featured evidence
1.7%
NCT03255382 · Phase 3 · registry result, not featured evidence
0%600 mg
NCT05283135 · Phase 2 · registry result, not featured evidence
10%300 mg
NCT05283135 · Phase 2 · registry result, not featured evidence
8.7%180 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
13.8%90 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
0%150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
3.6%150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
1.9%150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
—150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
7.4%75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
3.4%75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
1.8%75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
0%180 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
14.6%90 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
11.6%18 mg
NCT02054481 · Phase 2 · registry result, not featured evidence
6.2%100 mgf
NCT01729754 · Phase 3 · monotherapy
show 24 more results
4.9%200 mg
NCT01729754 · Phase 3 · monotherapy
1.6%100 mg
NCT01722331 · Phase 3 · monotherapy
1.9%100 mg
NCT01722331 · Phase 3 · monotherapy
4.4%100 mg
NCT01722331 · Phase 3 · monotherapy
2.6%200 mg
NCT01722331 · Phase 3 · monotherapy
2.2%200 mg
NCT01722331 · Phase 3 · monotherapy
5.8%200 mg
NCT01722331 · Phase 3 · monotherapy
—100 mg
NCT03897075 · Phase 3
5.9%100 mg
NCT03897075 · Phase 3
0%
NCT04271540 · Phase 4 · registry result, not featured evidence
0%
NCT04541329 · Phase 4 · registry result, not featured evidence
7.3%100 mg
NCT03718299 · Phase 4 · registry result, not featured evidence
1.1%100 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
3.9%100 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
1.5%100 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
2.3%200 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
3.8%200 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
2.7%200 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
1.1%25 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
5.3%25 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
1.1%25 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
0%5 mg
NCT01225731 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
f
viral upper respiratory tract infection 6.6% (placebo 5.9%)
upper respiratory tract infection 5.6% (placebo 2%)
headache 3% (placebo 2%)
NCT02684370 · Phase 3
show 48 more results
viral upper respiratory tract infection 13.5% (placebo 5.9%)
upper respiratory tract infection 10.1% (placebo 2%)
headache 1.7% (placebo 2%)
NCT02684370 · Phase 3
nasopharyngitis 5.2% (placebo 6%)
headache 3.4% (placebo 0%)
arthralgia 1.7% (placebo 2%)
NCT02672852 · Phase 3
nasopharyngitis 20.7% (placebo 6%)
upper respiratory tract infection 14.4% (placebo 5%)
arthralgia 9% (placebo 2%)
NCT02672852 · Phase 3
headache 16.7% (placebo 4.8%)
pyrexia 16.7% (placebo 0%)
abdominal pain 8.3% (placebo 0%)
NCT04435600 · Phase 3
nasopharyngitis 40% (placebo 9.5%)
covid-19 20% (placebo 9.5%)
conjunctivitis 10% (placebo 0%)
NCT04435600 · Phase 3
nasopharyngitis 22.7% (placebo 9.5%)
headache 18.2% (placebo 4.8%)
skin papilloma 13.6% (placebo 0%)
NCT04435600 · Phase 3
nasopharyngitis 18.5% (placebo 9.5%)
covid-19 9.3% (placebo 9.5%)
headache 5.6% (placebo 4.8%)
NCT04435600 · Phase 3
pyrexia 25% (placebo 0%)
bacterial vaginosis 12.5% (placebo 0%)
chills 12.5% (placebo 0%)
NCT04435600 · Phase 3
cough 15.4% (placebo 4.8%)
upper respiratory tract infection 15.4% (placebo 4.8%)
blood potassium increased 7.7% (placebo 0%)
NCT04435600 · Phase 3
nasopharyngitis 31.3% (placebo 9.5%)
pyrexia 12.5% (placebo 0%)
cough 9.4% (placebo 4.8%)
NCT04435600 · Phase 3
upper respiratory tract infection 3.7% (placebo 2%)
viral upper respiratory tract infection 3.4% (placebo 2%)
influenza 2% (placebo 1%)
NCT02684357 · Phase 3
viral upper respiratory tract infection 11.7% (placebo 2%)
upper respiratory tract infection 8.2% (placebo 2%)
diarrhoea 2.1% (placebo 3.1%)
NCT02684357 · Phase 3
viral upper respiratory tract infection 26.4%
upper respiratory tract infection 7.5%
headache 5.7%
NCT02694523 · Phase 3
viral upper respiratory tract infection 23.7%
hypertension 7.9%
upper respiratory tract infection 7.9%
NCT02694523 · Phase 3
viral upper respiratory tract infection 8.6%
upper respiratory tract infection 7%
headache 4%
NCT02694523 · Phase 3
viral upper respiratory tract infection 13.3%
upper respiratory tract infection 11.6%
hypertension 3.1%
NCT02694523 · Phase 3
upper respiratory tract infection 7.3% (placebo 3.7%)
covid-19 3.6% (placebo 3.7%)
nasopharyngitis 3.6% (placebo 3.7%)
NCT05969223 · Phase 4
upper respiratory tract infection 7.4% (placebo 3.7%)
covid-19 3.7% (placebo 3.7%)
nasopharyngitis 3.7% (placebo 3.7%)
NCT05969223 · Phase 4
upper respiratory tract infection 11.8% (placebo 3.7%)
covid-19 7.8% (placebo 3.7%)
nasopharyngitis 2% (placebo 3.7%)
NCT05969223 · Phase 4
upper respiratory tract infection 11.8% (placebo 3.7%)
covid-19 7.8% (placebo 3.7%)
nasopharyngitis 2% (placebo 3.7%)
NCT05969223 · Phase 4
covid-19 11%
nasopharyngitis 3.4%
headache 2.5%
NCT04908475 · Phase 4 · registry result, not featured evidence
covid-19 12.5%
nasopharyngitis 10.4%
hypertension 6.3%
NCT04908475 · Phase 4 · registry result, not featured evidence
covid-19 11.8%
nasopharyngitis 9.8%
upper respiratory tract infection 5.9%
NCT04908475 · Phase 4 · registry result, not featured evidence
covid-19 16.4%
nasopharyngitis 9.5%
hypertension 5.2%
NCT04908475 · Phase 4 · registry result, not featured evidence
150 mg
nasopharyngitis 22.1%
covid-19 16.6%
upper respiratory tract infection 14.4%
NCT03047395 · Phase 3 · registry result, not featured evidence
covid-19 2.3% (placebo 2.3%)
NCT04713592 · Phase 3 · registry result, not featured evidence
covid-19 14.3% (placebo 2.3%)
NCT04713592 · Phase 3 · registry result, not featured evidence
covid-19 8.6%
nasopharyngitis 5.7%
NCT04102007 · Phase 3 · registry result, not featured evidence
150 mg
viral upper respiratory tract infection 75%
otitis media 50%
acne 25%
NCT03022045 · Phase 3 · registry result, not featured evidence
150 mg
dehydration 50%
abdominal pain upper 25%
acne 25%
NCT03022045 · Phase 3 · registry result, not featured evidence
75 mg
viral upper respiratory tract infection 60%
constipation 20%
diarrhoea 20%
NCT03022045 · Phase 3 · registry result, not featured evidence
75 mg
alanine aminotransferase increased 25%
aspartate aminotransferase increased 25%
erythema 25%
NCT03022045 · Phase 3 · registry result, not featured evidence
nasopharyngitis 7.4%
upper respiratory tract infection 5.6%
NCT03875508 · Phase 3 · registry result, not featured evidence
nasopharyngitis 21.3%
upper respiratory tract infection 12.8%
arthralgia 5.5%
NCT03478787 · Phase 3 · registry result, not featured evidence
nasopharyngitis 58.3%
headache 8.3%
oropharyngeal pain 8.3%
NCT03255382 · Phase 3 · registry result, not featured evidence
600 mg
upper respiratory infection 50%
common cold 30%
covid-19 infection 30%
NCT05283135 · Phase 2 · registry result, not featured evidence
300 mg
upper respiratory infection 20%
bleeding internal hemorrhoids 10%
bursitis, left elbow 10%
NCT05283135 · Phase 2 · registry result, not featured evidence
180 mg
upper respiratory tract infection 17.4%
dermatitis contact 13%
nasopharyngitis 13%
NCT02203851 · Phase 2 · registry result, not featured evidence
90 mg
nasopharyngitis 18.4%
upper respiratory tract infection 12.6%
arthralgia 10.3%
NCT02203851 · Phase 2 · registry result, not featured evidence
150 mg
nasopharyngitis 29.6% (placebo 13.8%)
arthralgia 11.1% (placebo 1.7%)
oral herpes 7.4% (placebo 0%)
NCT03000075 · Phase 2 · registry result, not featured evidence
150 mg
nasopharyngitis 18.2% (placebo 13.8%)
arthralgia 3.6% (placebo 1.7%)
back pain 1.8% (placebo 1.7%)
NCT03000075 · Phase 2 · registry result, not featured evidence
150 mg
nasopharyngitis 20.4% (placebo 13.8%)
dental caries 7.4% (placebo 1.7%)
blood triglycerides increased 5.6% (placebo 0%)
NCT03000075 · Phase 2 · registry result, not featured evidence
75 mg
nasopharyngitis 29.6% (placebo 13.8%)
arthralgia 11.1% (placebo 1.7%)
asteatosis 7.4% (placebo 0%)
NCT03000075 · Phase 2 · registry result, not featured evidence
75 mg
diabetes mellitus 5.2% (placebo 1.7%)
nasopharyngitis 5.2% (placebo 13.8%)
back pain 3.4% (placebo 1.7%)
NCT03000075 · Phase 2 · registry result, not featured evidence
75 mg
nasopharyngitis 21.4% (placebo 13.8%)
hepatic function abnormal 5.4% (placebo 0%)
influenza 5.4% (placebo 0%)
NCT03000075 · Phase 2 · registry result, not featured evidence
180 mg
nasopharyngitis 26.2%
arthralgia 7.1%
headache 7.1%
NCT02054481 · Phase 2 · registry result, not featured evidence
90 mg
nasopharyngitis 34.1%
back pain 9.8%
gastroenteritis 9.8%
NCT02054481 · Phase 2 · registry result, not featured evidence
18 mg
nasopharyngitis 34.9%
headache 11.6%
folliculitis 7%
NCT02054481 · Phase 2 · registry result, not featured evidence
100 mgf
nasopharyngitis 23% (placebo 7.7%)
headache 6% (placebo 3.8%)
arthralgia 5.3% (placebo 1.9%)
NCT01729754 · Phase 3 · monotherapy
show 22 more results
200 mg
nasopharyngitis 22.6% (placebo 7.7%)
headache 5.7% (placebo 3.8%)
upper respiratory tract infection 5.1% (placebo 0.6%)
NCT01729754 · Phase 3 · monotherapy
100 mg
nasopharyngitis 7.8% (placebo 5.2%)
upper respiratory tract infection 3.2% (placebo 5.8%)
psoriasis 0.6% (placebo 5.2%)
NCT01722331 · Phase 3 · monotherapy
100 mg
nasopharyngitis 6.4% (placebo 5.2%)
upper respiratory tract infection 4.3% (placebo 5.8%)
psoriasis 0.5% (placebo 5.2%)
NCT01722331 · Phase 3 · monotherapy
100 mg
nasopharyngitis 15.2% (placebo 5.2%)
upper respiratory tract infection 8.2% (placebo 5.8%)
psoriasis 2.8% (placebo 5.2%)
NCT01722331 · Phase 3 · monotherapy
200 mg
nasopharyngitis 6.5% (placebo 5.2%)
upper respiratory tract infection 4.9% (placebo 5.8%)
psoriasis 0% (placebo 5.2%)
NCT01722331 · Phase 3 · monotherapy
200 mg
upper respiratory tract infection 5.4% (placebo 5.8%)
nasopharyngitis 4.6% (placebo 5.2%)
psoriasis 0.8% (placebo 5.2%)
NCT01722331 · Phase 3 · monotherapy
200 mg
nasopharyngitis 12.2% (placebo 5.2%)
upper respiratory tract infection 10.3% (placebo 5.8%)
psoriasis 2.5% (placebo 5.2%)
NCT01722331 · Phase 3 · monotherapy
100 mg
covid-19 11.8% (placebo 10.4%)
skin and subcutaneous tissue disorders 9.8% (placebo 4.2%)
upper respiratory tract infection 9.8% (placebo 8.3%)
NCT03897075 · Phase 3
covid infection 9.7%
NCT04271540 · Phase 4 · registry result, not featured evidence
100 mg
psoriasis 12.7%
hypertension 9.1%
dermatitis 5.5%
NCT03718299 · Phase 4 · registry result, not featured evidence
100 mg
nasopharyngitis 14.6% (placebo 20%)
diarrhoea 6.7% (placebo 6.7%)
headache 6.7% (placebo 8.9%)
NCT01225731 · Phase 2 · registry result, not featured evidence
100 mg
nasopharyngitis 22.2% (placebo 20%)
headache 8.5% (placebo 8.9%)
back pain 5.2% (placebo 0%)
NCT01225731 · Phase 2 · registry result, not featured evidence
100 mg
nasopharyngitis 8.8% (placebo 20%)
back pain 3.6% (placebo 0%)
headache 3.6% (placebo 8.9%)
NCT01225731 · Phase 2 · registry result, not featured evidence
200 mg
nasopharyngitis 12.8% (placebo 20%)
headache 8.1% (placebo 8.9%)
pruritus 4.7% (placebo 8.9%)
NCT01225731 · Phase 2 · registry result, not featured evidence
200 mg
nasopharyngitis 16.5% (placebo 20%)
gastroenteritis 6.3% (placebo 2.2%)
upper respiratory tract infection 5.1% (placebo 0%)
NCT01225731 · Phase 2 · registry result, not featured evidence
200 mg
nasopharyngitis 6.7% (placebo 20%)
upper respiratory tract infection 4% (placebo 0%)
bronchiitis 2.7% (placebo 4.4%)
NCT01225731 · Phase 2 · registry result, not featured evidence
25 mg
nasopharyngitis 13.2% (placebo 20%)
diarrhoea 5.5% (placebo 6.7%)
headache 5.5% (placebo 8.9%)
NCT01225731 · Phase 2 · registry result, not featured evidence
25 mg
nasopharyngitis 25.5% (placebo 20%)
gastroenteritis 5.3% (placebo 2.2%)
back pain 4.3% (placebo 0%)
NCT01225731 · Phase 2 · registry result, not featured evidence
25 mg
nasopharyngitis 6.9% (placebo 20%)
back pain 3.4% (placebo 0%)
bronchiitis 2.3% (placebo 4.4%)
NCT01225731 · Phase 2 · registry result, not featured evidence
5 mg
nasopharyngitis 16.7% (placebo 20%)
bronchiitis 7.1% (placebo 4.4%)
cough 7.1% (placebo 4.4%)
NCT01225731 · Phase 2 · registry result, not featured evidence
5 mg
nasopharyngitis 23.1% (placebo 20%)
acute tonsilitis 7.7% (placebo 0%)
blood pressure systolic increased 7.7% (placebo 0%)
NCT01225731 · Phase 2 · registry result, not featured evidence
5 mg
abdominal pain upper 8.3% (placebo 0%)
back pain 8.3% (placebo 0%)
dyspnoea 8.3% (placebo 0%)
NCT01225731 · Phase 2 · registry result, not featured evidence

Notes

  1. aTrial phases differ: Phase 3 versus Phase 4.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dTrial phases differ: Phase 3 versus Phase 2.
  5. eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  6. fPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

risankizumab

sPGA (0 36.8% (n=304) vs 2% (n=102) placebo @ 16wk
responder rate · % of participants
NCT02684370 · Phase 3
show 15 more results
36.8% (n=304) vs 14% (n=100) Ustekinumab @ 16wk
NCT02684370 · Phase 3
57.6% (n=304) vs 21% (n=100) Ustekinumab @ 52wk
NCT02684370 · Phase 3
46.4% (n=407) vs 1% (n=100) placebo @ 16wk
NCT02672852 · Phase 3
51% (n=294) vs 3.1% (n=98) placebo @ 16wk
NCT02684357 · Phase 3
51% (n=294) vs 25.3% (n=99) Ustekinumab @ 16wk
NCT02684357 · Phase 3
59.5% (n=294) vs 30.3% (n=99) Ustekinumab @ 52wk
NCT02684357 · Phase 3
39.6% (n=53) vs 7.1% (n=56) Adalimumab @ 44wk
NCT02694523 · Phase 3
50.9% (n=55) vs 5.6% (n=54) placebo @ 16wk
NCT05969223 · Phase 4
39% (n=105) vs 1.9% (n=52) placebo @ 16wk
NCT03875482 · Phase 3 · registry result, not featured evidence
1.7% (n=60) vs 0% (n=60) Fumaderm @ 4wk
NCT03255382 · Phase 3 · registry result, not featured evidence
10% (n=60) vs 1.7% (n=60) Fumaderm @ 8wk
NCT03255382 · Phase 3 · registry result, not featured evidence
21.7% (n=60) vs 3.3% (n=60) Fumaderm @ 12wk
NCT03255382 · Phase 3 · registry result, not featured evidence
36.7% (n=60) vs 3.3% (n=60) Fumaderm @ 16wk
NCT03255382 · Phase 3 · registry result, not featured evidence
48.3% (n=60) vs 6.7% (n=60) Fumaderm @ 20wk
NCT03255382 · Phase 3 · registry result, not featured evidence
51.7% (n=60) vs 5% (n=60) Fumaderm @ 24wk
NCT03255382 · Phase 3 · registry result, not featured evidence
DLQI 0/1 65.8% (n=304) vs 7.8% (n=102) placebo @ 16wk
responder rate · % of participants
NCT02684370 · Phase 3
show 7 more results
65.8% (n=304) vs 43% (n=100) Ustekinumab @ 16wk
NCT02684370 · Phase 3
65.4% (n=407) vs 3% (n=100) placebo @ 16wk
NCT02672852 · Phase 3
66.7% (n=294) vs 4.1% (n=98) placebo @ 16wk
NCT02684357 · Phase 3
66.7% (n=294) vs 46.5% (n=99) Ustekinumab @ 16wk
NCT02684357 · Phase 3
60% (n=55) vs 3.7% (n=54) placebo @ 16wk
NCT05969223 · Phase 4
48.3% (n=60) vs 10% (n=60) Fumaderm @ 16wk
NCT03255382 · Phase 3 · registry result, not featured evidence
66.7% (n=60) vs 10% (n=60) Fumaderm @ 24wk
NCT03255382 · Phase 3 · registry result, not featured evidence
PSS Total -5.608 vs 0.157 placebo score @ 16wk
absolute change · score
NCT02684370 · Phase 3
show 3 more results
-6.013 vs -1.036 placebo score @ 16wk
NCT05969223 · Phase 4
-8.7 vs -5.5 Fumaderm score @ 16wk
NCT03255382 · Phase 3 · registry result, not featured evidence
-9.5 vs -5.6 Fumaderm score @ 24wk
NCT03255382 · Phase 3 · registry result, not featured evidence
sPGA 0/1 88.9% (n=27) @ 52wk150 mg
responder rate · % of participants
No placebo or comparator arm
NCT03000075 · Phase 2 · registry result, not featured evidence
show 12 more results
94.5% (n=55) @ 52wk150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
96.3% (n=27) @ 52wk75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
84.5% (n=58) @ 52wk75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
68.8% (n=32) @ 48wk180 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
70.4% (n=27) @ 48wk90 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
63.6% (n=22) @ 48wk18 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
62.5% (n=8) @ 16wk
NCT04435600 · Phase 3
62.5% (n=8) @ 16wk
NCT04435600 · Phase 3
57.4% (n=244) @ 16wk*
NCT04102007 · Phase 3 · registry result, not featured evidence · converted to % from 140 Participants as posted
62.3% (n=244) @ 52wk*
NCT04102007 · Phase 3 · registry result, not featured evidence · converted to % from 152 Participants as posted
81.5% (n=108) @ 16wk
NCT03875508 · Phase 3 · registry result, not featured evidence
66.7% (n=27) @ 48wk
NCT02203851 · Phase 2 · registry result, not featured evidence
PASI 50 100% (n=32) @ 48wk180 mg
responder rate · % of participants
No placebo or comparator arm
NCT02203851 · Phase 2 · registry result, not featured evidence
show 4 more results
96.3% (n=27) @ 48wk90 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
95.5% (n=22) @ 48wk18 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
87.5% (n=8) @ 16wk
NCT04435600 · Phase 3
100% (n=27) @ 48wk
NCT02203851 · Phase 2 · registry result, not featured evidence
PASI 90 75% (n=4) @ 16wk150 mg
responder rate · % of participants
No placebo or comparator arm
NCT03022045 · Phase 3 · registry result, not featured evidence
show 13 more results
100% (n=4) @ 16wk150 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
85.2% (n=27) @ 52wk150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
92.7% (n=55) @ 52wk150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
100% (n=4) @ 16wk75 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
60% (n=5) @ 16wk75 mg
NCT03022045 · Phase 3 · registry result, not featured evidence
81.5% (n=27) @ 52wk75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
86.2% (n=58) @ 52wk75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
71.9% (n=32) @ 48wk180 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
77.8% (n=27) @ 48wk90 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
72.7% (n=22) @ 48wk18 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
87.5% (n=8) @ 16wk
NCT04435600 · Phase 3
66.7% (n=108) @ 16wk
NCT03875508 · Phase 3 · registry result, not featured evidence
74.1% (n=27) @ 48wk
NCT02203851 · Phase 2 · registry result, not featured evidence
PASI 100 44.4% (n=27) @ 52wk150 mg
responder rate · % of participants
No placebo or comparator arm
NCT03000075 · Phase 2 · registry result, not featured evidence
show 15 more results
41.8% (n=55) @ 52wk150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
40.7% (n=27) @ 52wk75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
43.1% (n=58) @ 52wk75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
77.8% (n=9) @ 28wk*600 mg
NCT05283135 · Phase 2 · registry result, not featured evidence · converted to % from 7 Participants as posted
66.7% (n=9) @ 40wk*600 mg
NCT05283135 · Phase 2 · registry result, not featured evidence · converted to % from 6 Participants as posted
44.4% (n=9) @ 52wk*600 mg
NCT05283135 · Phase 2 · registry result, not featured evidence · converted to % from 4 Participants as posted
88.9% (n=9) @ 28wk*300 mg
NCT05283135 · Phase 2 · registry result, not featured evidence · converted to % from 8 Participants as posted
66.7% (n=9) @ 40wk*300 mg
NCT05283135 · Phase 2 · registry result, not featured evidence · converted to % from 6 Participants as posted
44.4% (n=9) @ 52wk*300 mg
NCT05283135 · Phase 2 · registry result, not featured evidence · converted to % from 4 Participants as posted
50% (n=32) @ 48wk180 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
55.6% (n=27) @ 48wk90 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
54.5% (n=22) @ 48wk18 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
25% (n=8) @ 16wk
NCT04435600 · Phase 3
46.3% (n=108) @ 16wk
NCT03875508 · Phase 3 · registry result, not featured evidence
55.6% (n=27) @ 48wk
NCT02203851 · Phase 2 · registry result, not featured evidence
PASI 75 88.9% (n=27) @ 52wk150 mg
responder rate · % of participants
No placebo or comparator arm
NCT03000075 · Phase 2 · registry result, not featured evidence
show 9 more results
96.4% (n=55) @ 52wk150 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
100% (n=27) @ 52wk75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
94.8% (n=58) @ 52wk75 mg
NCT03000075 · Phase 2 · registry result, not featured evidence
90.6% (n=32) @ 48wk180 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
92.6% (n=27) @ 48wk90 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
86.4% (n=22) @ 48wk18 mg
NCT02203851 · Phase 2 · registry result, not featured evidence
87.5% (n=8) @ 16wk
NCT04435600 · Phase 3
84.3% (n=108) @ 16wk
NCT03875508 · Phase 3 · registry result, not featured evidence
96.3% (n=27) @ 48wk
NCT02203851 · Phase 2 · registry result, not featured evidence
CDLQI -7.4 vs -6.8 Ustekinumab score @ 16wk
absolute change · score
NCT04435600 · Phase 3
CDLQI -7.5 score @ 16wk
absolute change · score
No placebo or comparator arm
NCT04435600 · Phase 3
FDLQI -6.9 vs -6 Ustekinumab score @ 16wk
absolute change · score
NCT04435600 · Phase 3
FDLQI -5.8 score @ 16wk
absolute change · score
No placebo or comparator arm
NCT04435600 · Phase 3

+ 38 further endpoints in the CSV export.

tildrakizumab

PASI 75 61.2% (n=307) vs 5.8% (n=156) placebo @ 12wk100 mg
responder rate · % of participants
Extension (open-label)
NCT01729754 · Phase 3 · monotherapy
show 5 more results
73.5% (n=294) vs 53.6% (n=289) Etanercept @ 28wk100 mg
NCT01729754 · Phase 3 · monotherapy
63.8% (n=309) vs 5.8% (n=154) placebo @ 12wk100 mg
NCT01722331 · Phase 3 · monotherapy
65.6% (n=314) vs 5.8% (n=156) placebo @ 12wk200 mg
NCT01729754 · Phase 3 · monotherapy
72.6% (n=299) vs 53.6% (n=289) Etanercept @ 28wk200 mg
NCT01729754 · Phase 3 · monotherapy
62.3% (n=308) vs 5.8% (n=154) placebo @ 12wk200 mg
NCT01722331 · Phase 3 · monotherapy
sPGA 0/1 54.7% (n=307) vs 4.5% (n=156) placebo @ 12wk100 mg
responder rate · % of participants
Extension (open-label)
NCT01729754 · Phase 3 · monotherapy
show 5 more results
64.6% (n=294) vs 45.3% (n=289) Etanercept @ 28wk100 mg
NCT01729754 · Phase 3 · monotherapy
57.9% (n=309) vs 7.1% (n=154) placebo @ 12wk100 mg
NCT01722331 · Phase 3 · monotherapy
59.2% (n=314) vs 4.5% (n=156) placebo @ 12wk200 mg
NCT01729754 · Phase 3 · monotherapy
69.2% (n=299) vs 45.3% (n=289) Etanercept @ 28wk200 mg
NCT01729754 · Phase 3 · monotherapy
59.1% (n=308) vs 7.1% (n=154) placebo @ 12wk200 mg
NCT01722331 · Phase 3 · monotherapy
PASI 75 97.6% (n=212) @ 40wk100 mg
responder rate · % of participants
Extension (open-label)
No placebo or comparator arm
NCT01729754 · Phase 3 · monotherapy
show 11 more results
66.7% (n=21) @ 40wk100 mg / 200 mg
NCT01729754 · Phase 3 · monotherapy
61.9% (n=21) @ 40wk100 mg
NCT01729754 · Phase 3 · monotherapy
93.6% (n=204) @ 52wk100 mg
NCT01729754 · Phase 3 · monotherapy
78.9% (n=19) @ 52wk100 mg / 200 mg
NCT01729754 · Phase 3 · monotherapy
68.4% (n=19) @ 52wk100 mg
NCT01729754 · Phase 3 · monotherapy
96.3% (n=107) @ 40wk200 mg
NCT01729754 · Phase 3 · monotherapy
92.6% (n=108) @ 40wk200 mg / 100 mg
NCT01729754 · Phase 3 · monotherapy
63.3% (n=60) @ 40wk200 mg
NCT01729754 · Phase 3 · monotherapy
97.1% (n=105) @ 52wk200 mg
NCT01729754 · Phase 3 · monotherapy
94.2% (n=104) @ 52wk200 mg / 100 mg
NCT01729754 · Phase 3 · monotherapy
66.7% (n=60) @ 52wk200 mg
NCT01729754 · Phase 3 · monotherapy
sPGA 0/1 84.9% (n=212) @ 40wk100 mg
responder rate · % of participants
Extension (open-label)
No placebo or comparator arm
NCT01729754 · Phase 3 · monotherapy
show 11 more results
38.1% (n=21) @ 40wk100 mg / 200 mg
NCT01729754 · Phase 3 · monotherapy
57.1% (n=21) @ 40wk100 mg
NCT01729754 · Phase 3 · monotherapy
79.4% (n=204) @ 52wk100 mg
NCT01729754 · Phase 3 · monotherapy
42.1% (n=19) @ 52wk100 mg / 200 mg
NCT01729754 · Phase 3 · monotherapy
57.9% (n=19) @ 52wk100 mg
NCT01729754 · Phase 3 · monotherapy
83.2% (n=107) @ 40wk200 mg
NCT01729754 · Phase 3 · monotherapy
79.2% (n=106) @ 40wk200 mg / 100 mg
NCT01729754 · Phase 3 · monotherapy
57.6% (n=59) @ 40wk200 mg
NCT01729754 · Phase 3 · monotherapy
84.8% (n=105) @ 52wk200 mg
NCT01729754 · Phase 3 · monotherapy
77.7% (n=103) @ 52wk200 mg / 100 mg
NCT01729754 · Phase 3 · monotherapy
50.8% (n=59) @ 52wk200 mg
NCT01729754 · Phase 3 · monotherapy
PASI 90 38.8% (n=307) vs 1.3% (n=156) placebo @ 12wk100 mg
responder rate · % of participants
Extension (open-label)
NCT01729754 · Phase 3 · monotherapy
show 5 more results
55.5% (n=290) vs 30.7% (n=277) Etanercept @ 28wk100 mg
NCT01729754 · Phase 3 · monotherapy
34.6% (n=309) vs 2.6% (n=154) placebo @ 12wk100 mg
NCT01722331 · Phase 3 · monotherapy
36.6% (n=314) vs 1.3% (n=156) placebo @ 12wk200 mg
NCT01729754 · Phase 3 · monotherapy
57.7% (n=293) vs 30.7% (n=277) Etanercept @ 28wk200 mg
NCT01729754 · Phase 3 · monotherapy
35.4% (n=308) vs 2.6% (n=154) placebo @ 12wk200 mg
NCT01722331 · Phase 3 · monotherapy
PASI 90 78.8% (n=212) @ 40wk100 mg
responder rate · % of participants
Extension (open-label)
No placebo or comparator arm
NCT01729754 · Phase 3 · monotherapy
show 11 more results
23.8% (n=21) @ 40wk100 mg / 200 mg
NCT01729754 · Phase 3 · monotherapy
42.9% (n=21) @ 40wk100 mg
NCT01729754 · Phase 3 · monotherapy
78.4% (n=204) @ 52wk100 mg
NCT01729754 · Phase 3 · monotherapy
26.3% (n=19) @ 52wk100 mg / 200 mg
NCT01729754 · Phase 3 · monotherapy
42.1% (n=19) @ 52wk100 mg
NCT01729754 · Phase 3 · monotherapy
76.6% (n=107) @ 40wk200 mg
NCT01729754 · Phase 3 · monotherapy
73.1% (n=108) @ 40wk200 mg / 100 mg
NCT01729754 · Phase 3 · monotherapy
28.3% (n=60) @ 40wk200 mg
NCT01729754 · Phase 3 · monotherapy
81.9% (n=105) @ 52wk200 mg
NCT01729754 · Phase 3 · monotherapy
68.3% (n=104) @ 52wk200 mg / 100 mg
NCT01729754 · Phase 3 · monotherapy
31.7% (n=60) @ 52wk200 mg
NCT01729754 · Phase 3 · monotherapy
PASI 100 12.4% (n=307) vs 0% (n=156) placebo @ 12wk100 mg
responder rate · % of participants
Extension (open-label)
NCT01729754 · Phase 3 · monotherapy
show 5 more results
22.8% (n=290) vs 11.2% (n=277) Etanercept @ 28wk100 mg
NCT01729754 · Phase 3 · monotherapy
13.9% (n=309) vs 1.3% (n=154) placebo @ 12wk100 mg
NCT01722331 · Phase 3 · monotherapy
11.8% (n=314) vs 0% (n=156) placebo @ 12wk200 mg
NCT01729754 · Phase 3 · monotherapy
27% (n=293) vs 11.2% (n=277) Etanercept @ 28wk200 mg
NCT01729754 · Phase 3 · monotherapy
14% (n=308) vs 1.3% (n=154) placebo @ 12wk200 mg
NCT01722331 · Phase 3 · monotherapy
PASI 100 33.5% (n=212) @ 40wk100 mg
responder rate · % of participants
Extension (open-label)
No placebo or comparator arm
NCT01729754 · Phase 3 · monotherapy
show 11 more results
0% (n=21) @ 40wk100 mg / 200 mg
NCT01729754 · Phase 3 · monotherapy
14.3% (n=21) @ 40wk100 mg
NCT01729754 · Phase 3 · monotherapy
35.3% (n=204) @ 52wk100 mg
NCT01729754 · Phase 3 · monotherapy
5.3% (n=19) @ 52wk100 mg / 200 mg
NCT01729754 · Phase 3 · monotherapy
31.6% (n=19) @ 52wk100 mg
NCT01729754 · Phase 3 · monotherapy
39.3% (n=107) @ 40wk200 mg
NCT01729754 · Phase 3 · monotherapy
38.9% (n=108) @ 40wk200 mg / 100 mg
NCT01729754 · Phase 3 · monotherapy
11.7% (n=60) @ 40wk200 mg
NCT01729754 · Phase 3 · monotherapy
46.7% (n=105) @ 52wk200 mg
NCT01729754 · Phase 3 · monotherapy
37.5% (n=104) @ 52wk200 mg / 100 mg
NCT01729754 · Phase 3 · monotherapy
10% (n=60) @ 52wk200 mg
NCT01729754 · Phase 3 · monotherapy
DLQI -10.2 vs -2 placebo score @ 12wk100 mg
absolute change · score
Extension (open-label)
NCT01729754 · Phase 3 · monotherapy
show 5 more results
-11.2 vs -9.5 Etanercept score @ 28wk100 mg
NCT01729754 · Phase 3 · monotherapy
-9.8 vs -2.3 placebo score @ 12wk100 mg
NCT01722331 · Phase 3 · monotherapy
-10.3 vs -2 placebo score @ 12wk200 mg
NCT01729754 · Phase 3 · monotherapy
-11.7 vs -9.5 Etanercept score @ 28wk200 mg
NCT01729754 · Phase 3 · monotherapy
-10 vs -2.3 placebo score @ 12wk200 mg
NCT01722331 · Phase 3 · monotherapy
DLQI -13.2 score @ 40wk100 mg
absolute change · score
Extension (open-label)
No placebo or comparator arm
NCT01729754 · Phase 3 · monotherapy
show 11 more results
-9 score @ 40wk100 mg / 200 mg
NCT01729754 · Phase 3 · monotherapy
-9.8 score @ 40wk100 mg
NCT01729754 · Phase 3 · monotherapy
-13.1 score @ 52wk100 mg
NCT01729754 · Phase 3 · monotherapy
-9.4 score @ 52wk100 mg / 200 mg
NCT01729754 · Phase 3 · monotherapy
-9.3 score @ 52wk100 mg
NCT01729754 · Phase 3 · monotherapy
-11.6 score @ 40wk200 mg
NCT01729754 · Phase 3 · monotherapy
-12 score @ 40wk200 mg / 100 mg
NCT01729754 · Phase 3 · monotherapy
-9.7 score @ 40wk200 mg
NCT01729754 · Phase 3 · monotherapy
-11.3 score @ 52wk200 mg
NCT01729754 · Phase 3 · monotherapy
-11.5 score @ 52wk200 mg / 100 mg
NCT01729754 · Phase 3 · monotherapy
-9.2 score @ 52wk200 mg
NCT01729754 · Phase 3 · monotherapy
DLQI 0/1 40.2% (n=296) vs 8% (n=150) placebo @ 12wk100 mg
responder rate · % of participants
Extension (open-label)
NCT01729754 · Phase 3 · monotherapy
show 5 more results
54.1% (n=290) vs 39.4% (n=282) Etanercept @ 28wk100 mg
NCT01729754 · Phase 3 · monotherapy
41.5% (n=304) vs 5.3% (n=150) placebo @ 12wk100 mg
NCT01722331 · Phase 3 · monotherapy
47.4% (n=306) vs 8% (n=150) placebo @ 12wk200 mg
NCT01729754 · Phase 3 · monotherapy
65% (n=297) vs 39.4% (n=282) Etanercept @ 28wk200 mg
NCT01729754 · Phase 3 · monotherapy
44.2% (n=299) vs 5.3% (n=150) placebo @ 12wk200 mg
NCT01722331 · Phase 3 · monotherapy
DLQI 0/1 71.2% (n=212) @ 40wk100 mg
responder rate · % of participants
Extension (open-label)
No placebo or comparator arm
NCT01729754 · Phase 3 · monotherapy
show 11 more results
9.5% (n=21) @ 40wk100 mg / 200 mg
NCT01729754 · Phase 3 · monotherapy
19% (n=21) @ 40wk100 mg
NCT01729754 · Phase 3 · monotherapy
68.8% (n=205) @ 52wk100 mg
NCT01729754 · Phase 3 · monotherapy
10.5% (n=19) @ 52wk100 mg / 200 mg
NCT01729754 · Phase 3 · monotherapy
42.1% (n=19) @ 52wk100 mg
NCT01729754 · Phase 3 · monotherapy
72.2% (n=108) @ 40wk200 mg
NCT01729754 · Phase 3 · monotherapy
68.5% (n=108) @ 40wk200 mg / 100 mg
NCT01729754 · Phase 3 · monotherapy
41.7% (n=60) @ 40wk200 mg
NCT01729754 · Phase 3 · monotherapy
72.4% (n=105) @ 52wk200 mg
NCT01729754 · Phase 3 · monotherapy
71.4% (n=105) @ 52wk200 mg / 100 mg
NCT01729754 · Phase 3 · monotherapy
40% (n=60) @ 52wk200 mg
NCT01729754 · Phase 3 · monotherapy

+ 24 further endpoints in the CSV export.

Psoriatic Arthritis

Shared mechanism: IL-23 p19 · full Psoriatic Arthritis pipeline

risankizumab · Skyrizi

Marketed by AbbVie and partners

Approved in Psoriatic Arthritismonoclonal antibody
Reliable signal

NCT03675308 · Phase 3 · active, not recruiting

Randomized, double-blind, placebo-controlled trial in 964 patients with a validated clinical response measure (ACR20 at week 24) as the primary endpoint, which risankizumab met (57.3% vs 33.5%, p<0.001). The protocol and the published report state a power calculation for the ACR20 endpoint based on about 880 patients, and 964 were randomized.

Next expected readout: August 2029 · NCT06865105 (registry estimate)

Reported efficacy

Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24 (Baseline and Week 24): Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 24 (Baseline and Week 24): Placebo 33.5 percentage of participants (95% CI 29.3 to 37.8) | Risankizumab 57.3 percentage of participants (95% CI 52.9 to 61.8) (met)

Result source: NCT03675308

tildrakizumab · Ilumya

Marketed by Sun Pharmaceutical Industries and partners

Approved in Psoriatic Arthritismonoclonal antibody
Partial signal

NCT04314544 · Phase 3 · completed

The study randomized 508 participants to tildrakizumab or placebo, with outcome assessors masked, and used the clinical ACR20 response as its primary endpoint. However, no results are posted, so whether the primary endpoint was met or missed is unknown.

Next expected readout: December 2028 · NCT04991116 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Psoriatic Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointrisankizumabtildrakizumab
ACR2061.9% vs 35.7%+26.2 vs placebo150 mg weeks 0, 4, and 16 · wk 16 · n 42NCT02719171
5 other results
  • 59% vs 35.7% 150 mg weeks 0 and 12 · wk 16 · n 39 · Phase 2 · primary NCT02719171
  • 60.5% vs 35.7% 150 mg weeks 0, 4, and 16; 150 mg weeks 0 and 12 · wk 16 · n 81 · Phase 2 · primary NCT02719171
  • 57.1% vs 35.7% 150 mg every 4 weeks · wk 16 · n 42 · Phase 2 · primary NCT02719171
  • 59.5% vs 35.7% 150 mg every 4 weeks; 150 mg weeks 0, 4, 16 · wk 16 · n 84 · Phase 2 · primary NCT02719171
  • 65% vs 35.7% 75 mg week 0 · wk 16 · n 20 · Phase 2 · primary NCT02719171
0.8% vs 0.5%+0.3 vs placeboI · wk 24 · n 78NCT02980692
3 other results
  • 0.8% vs 0.5% II · wk 24 · n 79 · Phase 2 · primary NCT02980692
  • 0.7% vs 0.5% Dose III · wk 24 · n 77 · Phase 2 · primary NCT02980692
  • 0.7% vs 0.5% Dose IV · wk 24 · n 78 · Phase 2 · primary NCT02980692
ACR5023.8% vs 11.9%+11.9 vs placebo150 mg weeks 0, 4, and 16 · wk 16 · n 42NCT02719171
5 other results
  • 38.5% vs 11.9% 150 mg weeks 0 and 12 · wk 16 · n 39 · Phase 2 · secondary NCT02719171
  • 30.9% vs 11.9% 150 mg weeks 0, 4, and 16; 150 mg weeks 0 and 12 · wk 16 · n 81 · Phase 2 · secondary NCT02719171
  • 23.8% vs 11.9% 150 mg every 4 weeks · wk 16 · n 42 · Phase 2 · secondary NCT02719171
  • 23.8% vs 11.9% 150 mg every 4 weeks; 150 mg weeks 0, 4, and 16 · wk 16 · n 84 · Phase 2 · secondary NCT02719171
  • 25% vs 11.9% 75 mg week 0 · wk 16 · n 20 · Phase 2 · secondary NCT02719171
—Not posted · NCT04314544
PASI 75—Not posted · NCT06624228—Not posted · NCT04314544
Minimal disease activity—Not posted · NCT06624228—Not posted · NCT04314544
HAQ-DI, change-0.2 vs -0.1−0.1 vs placebo150 mg weeks 0, 4, and 16 · wk 16 · n 40NCT02719171
5 other results
  • -0.2 vs -0.1 150 mg weeks 0 and 12 · wk 16 · n 38 · Phase 2 · secondary NCT02719171
  • -0.2 vs -0.1 150 mg weeks 0, 4, and 16; 150 mg weeks 0 and 12 · wk 16 · n 78 · Phase 2 · secondary NCT02719171
  • -0.2 vs -0.1 150 mg every 4 weeks · wk 16 · n 39 · Phase 2 · secondary NCT02719171
  • -0.2 vs -0.1 150 mg every 4 weeks; 150 mg weeks 0, 4, and 16 · wk 16 · n 79 · Phase 2 · secondary NCT02719171
  • -0.1 vs -0.1 75 mg week 0 · wk 16 · n 18 · Phase 2 · secondary NCT02719171
—Not posted · NCT04314544

ACR20

risankizumab
61.9% vs 35.7%+26.2 vs placebo150 mg weeks 0, 4, and 16 · wk 16 · n 42NCT02719171
5 other results
  • 59% vs 35.7% 150 mg weeks 0 and 12 · wk 16 · n 39 · Phase 2 · primary NCT02719171
  • 60.5% vs 35.7% 150 mg weeks 0, 4, and 16; 150 mg weeks 0 and 12 · wk 16 · n 81 · Phase 2 · primary NCT02719171
  • 57.1% vs 35.7% 150 mg every 4 weeks · wk 16 · n 42 · Phase 2 · primary NCT02719171
  • 59.5% vs 35.7% 150 mg every 4 weeks; 150 mg weeks 0, 4, 16 · wk 16 · n 84 · Phase 2 · primary NCT02719171
  • 65% vs 35.7% 75 mg week 0 · wk 16 · n 20 · Phase 2 · primary NCT02719171
tildrakizumab
0.8% vs 0.5%+0.3 vs placeboI · wk 24 · n 78NCT02980692
3 other results
  • 0.8% vs 0.5% II · wk 24 · n 79 · Phase 2 · primary NCT02980692
  • 0.7% vs 0.5% Dose III · wk 24 · n 77 · Phase 2 · primary NCT02980692
  • 0.7% vs 0.5% Dose IV · wk 24 · n 78 · Phase 2 · primary NCT02980692

ACR50

risankizumab
23.8% vs 11.9%+11.9 vs placebo150 mg weeks 0, 4, and 16 · wk 16 · n 42NCT02719171
5 other results
  • 38.5% vs 11.9% 150 mg weeks 0 and 12 · wk 16 · n 39 · Phase 2 · secondary NCT02719171
  • 30.9% vs 11.9% 150 mg weeks 0, 4, and 16; 150 mg weeks 0 and 12 · wk 16 · n 81 · Phase 2 · secondary NCT02719171
  • 23.8% vs 11.9% 150 mg every 4 weeks · wk 16 · n 42 · Phase 2 · secondary NCT02719171
  • 23.8% vs 11.9% 150 mg every 4 weeks; 150 mg weeks 0, 4, and 16 · wk 16 · n 84 · Phase 2 · secondary NCT02719171
  • 25% vs 11.9% 75 mg week 0 · wk 16 · n 20 · Phase 2 · secondary NCT02719171
tildrakizumab
—Not posted · NCT04314544

PASI 75

risankizumab
—Not posted · NCT06624228
tildrakizumab
—Not posted · NCT04314544

Minimal disease activity

risankizumab
—Not posted · NCT06624228
tildrakizumab
—Not posted · NCT04314544

HAQ-DI, change

risankizumab
-0.2 vs -0.1−0.1 vs placebo150 mg weeks 0, 4, and 16 · wk 16 · n 40NCT02719171
5 other results
  • -0.2 vs -0.1 150 mg weeks 0 and 12 · wk 16 · n 38 · Phase 2 · secondary NCT02719171
  • -0.2 vs -0.1 150 mg weeks 0, 4, and 16; 150 mg weeks 0 and 12 · wk 16 · n 78 · Phase 2 · secondary NCT02719171
  • -0.2 vs -0.1 150 mg every 4 weeks · wk 16 · n 39 · Phase 2 · secondary NCT02719171
  • -0.2 vs -0.1 150 mg every 4 weeks; 150 mg weeks 0, 4, and 16 · wk 16 · n 79 · Phase 2 · secondary NCT02719171
  • -0.1 vs -0.1 75 mg week 0 · wk 16 · n 18 · Phase 2 · secondary NCT02719171
tildrakizumab
—Not posted · NCT04314544
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety

Coverage. risankizumab: 6 of 6 rows · tildrakizumab: 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricrisankizumab
Rows use multiple source trials
tildrakizumab
ACR20
responder rate · % of participants
No placebo or comparator arm
75.2% (n=101) @ 52wka,b
NCT02986373 · Phase 2 · registry result, not featured evidence
0.8667% (n=60) @ 52wkDose IIIc,a,b
NCT02980692 · Phase 2 · registry result, not featured evidence
show 3 more doses
0.8133% (n=75) @ 52wkDose IV then SUNPG1623 II
NCT02980692 · Phase 2 · registry result, not featured evidence
0.9254% (n=67) @ 52wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
0.8906% (n=64) @ 52wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
HAQ-DI
absolute change · score
No placebo or comparator arm
-0.318 score @ 52wka,b
NCT02986373 · Phase 2 · registry result, not featured evidence
-0.4857 score @ 52wkDose IIIc,a,b
NCT02980692 · Phase 2 · registry result, not featured evidence
show 3 more doses
-0.4583 score @ 52wkDose IV then SUNPG1623 II
NCT02980692 · Phase 2 · registry result, not featured evidence
-0.4869 score @ 52wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-0.543 score @ 52wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
Dropout rate
—150 mgd
NCT03671148 · Phase 3
show 5 more results
26.9%
NCT02986373 · Phase 2 · registry result, not featured evidence
5.1%150 mg weeks 0 and 12
NCT02719171 · Phase 2 · registry result, not featured evidence
7.1%150 mg weeks 0, 4, and 16
NCT02719171 · Phase 2 · registry result, not featured evidence
9.5%150 mg every 4 weeks
NCT02719171 · Phase 2 · registry result, not featured evidence
10%75 mg week 0
NCT02719171 · Phase 2 · registry result, not featured evidence
100%200 mg q12 Weeksd
NCT03552276 · Phase 2/3 · registry result, not featured evidence
show 23 more results
16.6%200 mg q12 Weeks switched to 100 mg q12 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
—200 mg q12 Weeks, to 100 mg q12 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
100%200 mg q4 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
14.8%200 mg q4 Weeks switched to 100 mg q12 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
—200 mg q4 Weeks, to 100 mg q12 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
—200 mg, q12 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
—200 mg, q4 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
32.7%100 mg q12 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
—Dose III
NCT02980692 · Phase 2 · registry result, not featured evidence
—Dose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
—II
NCT02980692 · Phase 2 · registry result, not featured evidence
—I
NCT02980692 · Phase 2 · registry result, not featured evidence
—Dose III
NCT02980692 · Phase 2 · registry result, not featured evidence
—II
NCT02980692 · Phase 2 · registry result, not featured evidence
—I
NCT02980692 · Phase 2 · registry result, not featured evidence
—Dose IV then SUNPG1623 II
NCT02980692 · Phase 2 · registry result, not featured evidence
—Dose III
NCT02980692 · Phase 2 · registry result, not featured evidence
—II
NCT02980692 · Phase 2 · registry result, not featured evidence
—I
NCT02980692 · Phase 2 · registry result, not featured evidence
22.1%Dose III
NCT02980692 · Phase 2 · registry result, not featured evidence
9%Dose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
20.5%I
NCT02980692 · Phase 2 · registry result, not featured evidence
19%II
NCT02980692 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—150 mgd
NCT03671148 · Phase 3
show 5 more results
2.8%
NCT02986373 · Phase 2 · registry result, not featured evidence
0%150 mg weeks 0 and 12
NCT02719171 · Phase 2 · registry result, not featured evidence
0%150 mg weeks 0, 4, and 16
NCT02719171 · Phase 2 · registry result, not featured evidence
4.8%150 mg every 4 weeks
NCT02719171 · Phase 2 · registry result, not featured evidence
10%75 mg week 0
NCT02719171 · Phase 2 · registry result, not featured evidence
—200 mg q12 Weeksd
NCT03552276 · Phase 2/3 · registry result, not featured evidence
show 23 more results
—200 mg q12 Weeks switched to 100 mg q12 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
—200 mg q12 Weeks, to 100 mg q12 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
—200 mg q4 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
—200 mg q4 Weeks switched to 100 mg q12 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
—200 mg q4 Weeks, to 100 mg q12 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
—200 mg, q12 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
—200 mg, q4 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
—100 mg q12 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
—Dose III
NCT02980692 · Phase 2 · registry result, not featured evidence
—Dose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
—II
NCT02980692 · Phase 2 · registry result, not featured evidence
—I
NCT02980692 · Phase 2 · registry result, not featured evidence
—Dose III
NCT02980692 · Phase 2 · registry result, not featured evidence
—II
NCT02980692 · Phase 2 · registry result, not featured evidence
—I
NCT02980692 · Phase 2 · registry result, not featured evidence
—Dose IV then SUNPG1623 II
NCT02980692 · Phase 2 · registry result, not featured evidence
—Dose III
NCT02980692 · Phase 2 · registry result, not featured evidence
—II
NCT02980692 · Phase 2 · registry result, not featured evidence
—I
NCT02980692 · Phase 2 · registry result, not featured evidence
1.3%Dose III
NCT02980692 · Phase 2 · registry result, not featured evidence
2.6%Dose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
1.3%I
NCT02980692 · Phase 2 · registry result, not featured evidence
2.5%II
NCT02980692 · Phase 2 · registry result, not featured evidence
Serious AEs
4%150 mgd
NCT03671148 · Phase 3
show 5 more results
3.4%
NCT02986373 · Phase 2 · registry result, not featured evidence
5.1%150 mg weeks 0 and 12
NCT02719171 · Phase 2 · registry result, not featured evidence
0%150 mg weeks 0, 4, and 16
NCT02719171 · Phase 2 · registry result, not featured evidence
7.1%150 mg every 4 weeks
NCT02719171 · Phase 2 · registry result, not featured evidence
15%75 mg week 0
NCT02719171 · Phase 2 · registry result, not featured evidence
—200 mg q12 Weeksd
NCT03552276 · Phase 2/3 · registry result, not featured evidence
show 23 more results
—200 mg q12 Weeks switched to 100 mg q12 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
16.6%200 mg q12 Weeks, to 100 mg q12 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
—200 mg q4 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
—200 mg q4 Weeks switched to 100 mg q12 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
5.6%200 mg q4 Weeks, to 100 mg q12 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
9.1%200 mg, q12 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
60%200 mg, q4 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
14.3%100 mg q12 Weeks
NCT03552276 · Phase 2/3 · registry result, not featured evidence
2.6%Dose III
NCT02980692 · Phase 2 · registry result, not featured evidence
1.3%Dose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
2.5%II
NCT02980692 · Phase 2 · registry result, not featured evidence
2.6%I
NCT02980692 · Phase 2 · registry result, not featured evidence
0%Dose III
NCT02980692 · Phase 2 · registry result, not featured evidence
0%II
NCT02980692 · Phase 2 · registry result, not featured evidence
0%I
NCT02980692 · Phase 2 · registry result, not featured evidence
3.8%Dose IV then SUNPG1623 II
NCT02980692 · Phase 2 · registry result, not featured evidence
1.3%Dose III
NCT02980692 · Phase 2 · registry result, not featured evidence
1.3%II
NCT02980692 · Phase 2 · registry result, not featured evidence
3.8%I
NCT02980692 · Phase 2 · registry result, not featured evidence
—Dose III
NCT02980692 · Phase 2 · registry result, not featured evidence
—Dose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
—I
NCT02980692 · Phase 2 · registry result, not featured evidence
—II
NCT02980692 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
150 mgd
upper respiratory tract infection 7.6% (placebo 5%)
NCT03671148 · Phase 3
show 5 more results
viral upper respiratory tract infection 11%
NCT02986373 · Phase 2 · registry result, not featured evidence
150 mg weeks 0 and 12
viral upper respiratory tract infection 23.1% (placebo 4.8%)
headache 7.7% (placebo 7.1%)
abdominal pain 5.1% (placebo 2.4%)
NCT02719171 · Phase 2 · registry result, not featured evidence
150 mg weeks 0, 4, and 16
viral upper respiratory tract infection 11.9% (placebo 4.8%)
upper respiratory tract infection 7.1% (placebo 11.9%)
back pain 4.8% (placebo 2.4%)
NCT02719171 · Phase 2 · registry result, not featured evidence
150 mg every 4 weeks
viral upper respiratory tract infection 16.7% (placebo 4.8%)
cough 7.1% (placebo 4.8%)
fatigue 7.1% (placebo 0%)
NCT02719171 · Phase 2 · registry result, not featured evidence
75 mg week 0
viral upper respiratory tract infection 20% (placebo 4.8%)
abdominal discomfort 5% (placebo 0%)
alanine aminotransferase increased 5% (placebo 2.4%)
NCT02719171 · Phase 2 · registry result, not featured evidence
200 mg q12 Weeks, to 100 mg q12 Weeksd
covid-19 16.6%
nasopharyngitis 13.9%
urinary tract infection 11.9%
NCT03552276 · Phase 2/3 · registry result, not featured evidence
show 15 more results
200 mg q4 Weeks, to 100 mg q12 Weeks
covid-19 20.4%
upper respiratory tract infection 16.7%
nasopharyngitis 14.8%
NCT03552276 · Phase 2/3 · registry result, not featured evidence
200 mg, q12 Weeks
diarrhoea 18.2%
arthralgia 13.6%
arthritis 9.1%
NCT03552276 · Phase 2/3 · registry result, not featured evidence
200 mg, q4 Weeks
hypertension 40%
abdominal abscess 20%
alanine aminotransferase increased 20%
NCT03552276 · Phase 2/3 · registry result, not featured evidence
100 mg q12 Weeks
nasopharyngitis 14.3%
upper respiratory tract infection 14.3%
abdominal pain 8.2%
NCT03552276 · Phase 2/3 · registry result, not featured evidence
Dose III
headache 6.5% (placebo 3.8%)
nasopharyngitis 5.2% (placebo 6.3%)
upper respiratory tract infection 3.9% (placebo 1.3%)
NCT02980692 · Phase 2 · registry result, not featured evidence
Dose IV
diarrhoea 6.4% (placebo 0%)
headache 6.4% (placebo 3.8%)
nasopharyngitis 6.4% (placebo 6.3%)
NCT02980692 · Phase 2 · registry result, not featured evidence
II
hypertension 7.6% (placebo 6.3%)
sleep disorder 6.3% (placebo 1.3%)
upper respiratory tract infection 5.1% (placebo 1.3%)
NCT02980692 · Phase 2 · registry result, not featured evidence
I
nasopharyngitis 9% (placebo 6.3%)
headache 5.1% (placebo 3.8%)
hypertension 3.8% (placebo 6.3%)
NCT02980692 · Phase 2 · registry result, not featured evidence
Dose III
headache 2.6% (placebo 3.8%)
nasopharyngitis 2.6% (placebo 6.3%)
upper respiratory tract infection 2.6% (placebo 1.3%)
NCT02980692 · Phase 2 · registry result, not featured evidence
II
upper respiratory tract infection 5.1% (placebo 1.3%)
headache 3.8% (placebo 3.8%)
nasopharyngitis 2.5% (placebo 6.3%)
NCT02980692 · Phase 2 · registry result, not featured evidence
I
hypertension 5.1% (placebo 6.3%)
upper respiratory tract infection 3.8% (placebo 1.3%)
aspartate aminotransferase increased 2.6% (placebo 0%)
NCT02980692 · Phase 2 · registry result, not featured evidence
Dose IV then SUNPG1623 II
nasopharyngitis 9% (placebo 6.3%)
upper respiratory tract infection 5.1% (placebo 1.3%)
urinary tract infection 5.1% (placebo 3.8%)
NCT02980692 · Phase 2 · registry result, not featured evidence
Dose III
headache 1.3% (placebo 3.8%)
nasopharyngitis 1.3% (placebo 6.3%)
upper respiratory tract infection 1.3% (placebo 1.3%)
NCT02980692 · Phase 2 · registry result, not featured evidence
II
aspartate aminotransferase increased 1.3% (placebo 0%)
diarrhoea 0% (placebo 0%)
headache 0% (placebo 3.8%)
NCT02980692 · Phase 2 · registry result, not featured evidence
I
headache 3.8% (placebo 3.8%)
aspartate aminotransferase increased 2.6% (placebo 0%)
nasopharyngitis 2.6% (placebo 6.3%)
NCT02980692 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  4. dPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

risankizumab

Modified Sharp 0.12 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT02986373 · Phase 2 · registry result, not featured evidence
show 2 more results
0.38 score @ 24wk
NCT02986373 · Phase 2 · registry result, not featured evidence
0.34 score @ 48wk
NCT02986373 · Phase 2 · registry result, not featured evidence
SF-36 PCS 2.11 score @ 0wk
absolute change · score
No placebo or comparator arm
NCT02986373 · Phase 2 · registry result, not featured evidence
show 6 more results
3.63 score @ 4wk
NCT02986373 · Phase 2 · registry result, not featured evidence
3.63 score @ 12wk
NCT02986373 · Phase 2 · registry result, not featured evidence
3.76 score @ 24wk
NCT02986373 · Phase 2 · registry result, not featured evidence
4.27 score @ 36wk
NCT02986373 · Phase 2 · registry result, not featured evidence
5.08 score @ 48wk
NCT02986373 · Phase 2 · registry result, not featured evidence
4.47 score @ 52wk
NCT02986373 · Phase 2 · registry result, not featured evidence
SF-36 MCS 0.86 score @ 0wk
absolute change · score
No placebo or comparator arm
NCT02986373 · Phase 2 · registry result, not featured evidence
show 6 more results
2.79 score @ 4wk
NCT02986373 · Phase 2 · registry result, not featured evidence
2.22 score @ 12wk
NCT02986373 · Phase 2 · registry result, not featured evidence
4.08 score @ 24wk
NCT02986373 · Phase 2 · registry result, not featured evidence
3.44 score @ 36wk
NCT02986373 · Phase 2 · registry result, not featured evidence
3.36 score @ 48wk
NCT02986373 · Phase 2 · registry result, not featured evidence
4.33 score @ 52wk
NCT02986373 · Phase 2 · registry result, not featured evidence
ACR50 23.8% (n=42) vs 11.9% (n=42) placebo @ 16wk150 mg weeks 0, 4, and 16
responder rate · % of participants
NCT02719171 · Phase 2 · registry result, not featured evidence
show 5 more results
38.5% (n=39) vs 11.9% (n=42) placebo @ 16wk150 mg weeks 0 and 12
NCT02719171 · Phase 2 · registry result, not featured evidence
30.9% (n=81) vs 11.9% (n=42) placebo @ 16wk150 mg weeks 0, 4, and 16; 150 mg weeks 0 and 12
NCT02719171 · Phase 2 · registry result, not featured evidence
23.8% (n=42) vs 11.9% (n=42) placebo @ 16wk150 mg every 4 weeks
NCT02719171 · Phase 2 · registry result, not featured evidence
23.8% (n=84) vs 11.9% (n=42) placebo @ 16wk150 mg every 4 weeks; 150 mg weeks 0, 4, and 16
NCT02719171 · Phase 2 · registry result, not featured evidence
25% (n=20) vs 11.9% (n=42) placebo @ 16wk75 mg week 0
NCT02719171 · Phase 2 · registry result, not featured evidence
ACR70 7.1% (n=42) vs 0% (n=42) placebo @ 16wk150 mg weeks 0, 4, and 16
responder rate · % of participants
NCT02719171 · Phase 2 · registry result, not featured evidence
show 5 more results
25.6% (n=39) vs 0% (n=42) placebo @ 16wk150 mg weeks 0 and 12
NCT02719171 · Phase 2 · registry result, not featured evidence
16% (n=81) vs 0% (n=42) placebo @ 16wk150 mg weeks 0, 4, and 16; 150 mg weeks 0 and 12
NCT02719171 · Phase 2 · registry result, not featured evidence
14.3% (n=42) vs 0% (n=42) placebo @ 16wk150 mg every 4 weeks
NCT02719171 · Phase 2 · registry result, not featured evidence
10.7% (n=84) vs 0% (n=42) placebo @ 16wk150 mg every 4 weeks; 150 mg weeks 0, 4, and 16
NCT02719171 · Phase 2 · registry result, not featured evidence
15% (n=20) vs 0% (n=42) placebo @ 16wk75 mg week 0
NCT02719171 · Phase 2 · registry result, not featured evidence
Tender Joint Count -9.6 vs -7.9 placebo tender joints @ 16wk150 mg weeks 0, 4, and 16
absolute change · tender joints
NCT02719171 · Phase 2 · registry result, not featured evidence
show 5 more results
-10.4 vs -7.9 placebo tender joints @ 16wk150 mg weeks 0 and 12
NCT02719171 · Phase 2 · registry result, not featured evidence
-9.9 vs -7.9 placebo tender joints @ 16wk150 mg weeks 0, 4, and 16; 150 mg weeks 0 and 12
NCT02719171 · Phase 2 · registry result, not featured evidence
-7.8 vs -7.9 placebo tender joints @ 16wk150 mg every 4 weeks
NCT02719171 · Phase 2 · registry result, not featured evidence
-8.6 vs -7.9 placebo tender joints @ 16wk150 mg every 4 weeks; 150 mg weeks 0, 4, and 16
NCT02719171 · Phase 2 · registry result, not featured evidence
-10.8 vs -7.9 placebo tender joints @ 16wk75 mg week 0
NCT02719171 · Phase 2 · registry result, not featured evidence
Swollen Joint Count -7.8 vs -7.1 placebo swollen joints @ 16wk150 mg weeks 0, 4, and 16
absolute change · swollen joints
NCT02719171 · Phase 2 · registry result, not featured evidence
show 5 more results
-8.3 vs -7.1 placebo swollen joints @ 16wk150 mg weeks 0 and 12
NCT02719171 · Phase 2 · registry result, not featured evidence
-8.3 vs -7.1 placebo swollen joints @ 16wk150 mg weeks 0, 4, and 16; 150 mg weeks 0 and 12
NCT02719171 · Phase 2 · registry result, not featured evidence
-6.8 vs -7.1 placebo swollen joints @ 16wk150 mg every 4 weeks
NCT02719171 · Phase 2 · registry result, not featured evidence
-7.3 vs -7.1 placebo swollen joints @ 16wk150 mg every 4 weeks; 150 mg weeks 0, 4, and 16
NCT02719171 · Phase 2 · registry result, not featured evidence
-7.8 vs -7.1 placebo swollen joints @ 16wk75 mg week 0
NCT02719171 · Phase 2 · registry result, not featured evidence
HAQ-DI -0.163 vs -0.089 placebo score @ 16wk150 mg weeks 0, 4, and 16
absolute change · score
NCT02719171 · Phase 2 · registry result, not featured evidence
show 5 more results
-0.245 vs -0.089 placebo score @ 16wk150 mg weeks 0 and 12
NCT02719171 · Phase 2 · registry result, not featured evidence
-0.206 vs -0.089 placebo score @ 16wk150 mg weeks 0, 4, and 16; 150 mg weeks 0 and 12
NCT02719171 · Phase 2 · registry result, not featured evidence
-0.182 vs -0.089 placebo score @ 16wk150 mg every 4 weeks
NCT02719171 · Phase 2 · registry result, not featured evidence
-0.184 vs -0.089 placebo score @ 16wk150 mg every 4 weeks; 150 mg weeks 0, 4, and 16
NCT02719171 · Phase 2 · registry result, not featured evidence
-0.147 vs -0.089 placebo score @ 16wk75 mg week 0
NCT02719171 · Phase 2 · registry result, not featured evidence
SF-36 PCS 3.5 vs 1.93 placebo score @ 16wk150 mg weeks 0, 4, and 16
absolute change · score
NCT02719171 · Phase 2 · registry result, not featured evidence
show 5 more results
3.1 vs 1.93 placebo score @ 16wk150 mg weeks 0 and 12
NCT02719171 · Phase 2 · registry result, not featured evidence
3.32 vs 1.93 placebo score @ 16wk150 mg weeks 0, 4, and 16; 150 mg weeks 0 and 12
NCT02719171 · Phase 2 · registry result, not featured evidence
3.87 vs 1.93 placebo score @ 16wk150 mg every 4 weeks
NCT02719171 · Phase 2 · registry result, not featured evidence
3.8 vs 1.93 placebo score @ 16wk150 mg every 4 weeks; 150 mg weeks 0, 4, and 16
NCT02719171 · Phase 2 · registry result, not featured evidence
7.42 vs 1.93 placebo score @ 16wk75 mg week 0
NCT02719171 · Phase 2 · registry result, not featured evidence
SF-36 MCS 2.26 vs 0.48 placebo score @ 16wk150 mg weeks 0, 4, and 16
absolute change · score
NCT02719171 · Phase 2 · registry result, not featured evidence
show 5 more results
2.84 vs 0.48 placebo score @ 16wk150 mg weeks 0 and 12
NCT02719171 · Phase 2 · registry result, not featured evidence
2.29 vs 0.48 placebo score @ 16wk150 mg weeks 0, 4, and 16; 150 mg weeks 0 and 12
NCT02719171 · Phase 2 · registry result, not featured evidence
-0.36 vs 0.48 placebo score @ 16wk150 mg every 4 weeks
NCT02719171 · Phase 2 · registry result, not featured evidence
1.31 vs 0.48 placebo score @ 16wk150 mg every 4 weeks; 150 mg weeks 0, 4, and 16
NCT02719171 · Phase 2 · registry result, not featured evidence
-1.08 vs 0.48 placebo score @ 16wk75 mg week 0
NCT02719171 · Phase 2 · registry result, not featured evidence
Dactylitis -1.9 vs -2.6 placebo fingers and toes with dactylitis @ 16wk150 mg weeks 0, 4, and 16
absolute change · fingers and toes with dactylitis
NCT02719171 · Phase 2 · registry result, not featured evidence
show 5 more results
-2.9 vs -2.6 placebo fingers and toes with dactylitis @ 16wk150 mg weeks 0 and 12
NCT02719171 · Phase 2 · registry result, not featured evidence
-2.4 vs -2.6 placebo fingers and toes with dactylitis @ 16wk150 mg weeks 0, 4, and 16; 150 mg weeks 0 and 12
NCT02719171 · Phase 2 · registry result, not featured evidence
-1.1 vs -2.6 placebo fingers and toes with dactylitis @ 16wk150 mg every 4 weeks
NCT02719171 · Phase 2 · registry result, not featured evidence
-1.5 vs -2.6 placebo fingers and toes with dactylitis @ 16wk150 mg every 4 weeks; 150 mg weeks 0, 4, and 16
NCT02719171 · Phase 2 · registry result, not featured evidence
-3.5 vs -2.6 placebo fingers and toes with dactylitis @ 16wk75 mg week 0
NCT02719171 · Phase 2 · registry result, not featured evidence
SPARCC Enthesitis Index -2.4 vs -1.1 placebo score @ 16wk150 mg weeks 0, 4, and 16
absolute change · score
NCT02719171 · Phase 2 · registry result, not featured evidence
show 5 more results
-1.8 vs -1.1 placebo score @ 16wk150 mg weeks 0 and 12
NCT02719171 · Phase 2 · registry result, not featured evidence
-2.1 vs -1.1 placebo score @ 16wk150 mg weeks 0, 4, and 16; 150 mg weeks 0 and 12
NCT02719171 · Phase 2 · registry result, not featured evidence
-1.4 vs -1.1 placebo score @ 16wk150 mg every 4 weeks
NCT02719171 · Phase 2 · registry result, not featured evidence
-1.7 vs -1.1 placebo score @ 16wk150 mg every 4 weeks; 150 mg weeks 0, 4, and 16
NCT02719171 · Phase 2 · registry result, not featured evidence
-3.7 vs -1.1 placebo score @ 16wk75 mg week 0
NCT02719171 · Phase 2 · registry result, not featured evidence

+ 2 further endpoints in the CSV export.

tildrakizumab

ACR50 0% (n=78) @ 1wkI
responder rate · % of participants
No placebo or comparator arm
NCT02980692 · Phase 2 · registry result, not featured evidence
show 31 more results
0.0253% (n=79) @ 1wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
0.013% (n=77) @ 1wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
0.0128% (n=78) @ 1wkDose IV then SUNPG1623 II
NCT02980692 · Phase 2 · registry result, not featured evidence
0.0256% (n=78) @ 4wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
0.0506% (n=79) @ 4wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
0.0909% (n=77) @ 4wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
0.0385% (n=78) @ 4wkDose IV then SUNPG1623 II
NCT02980692 · Phase 2 · registry result, not featured evidence
0.1667% (n=78) @ 8wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
0.0759% (n=79) @ 8wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
0.1299% (n=77) @ 8wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
0.141% (n=78) @ 8wkDose IV then SUNPG1623 II
NCT02980692 · Phase 2 · registry result, not featured evidence
0.1795% (n=78) @ 12wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
0.1772% (n=79) @ 12wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
0.2078% (n=77) @ 12wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
0.1923% (n=78) @ 12wkDose IV then SUNPG1623 II
NCT02980692 · Phase 2 · registry result, not featured evidence
0.3077% (n=78) @ 16wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
0.2785% (n=79) @ 16wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
0.2727% (n=77) @ 16wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
0.2051% (n=78) @ 16wkDose IV then SUNPG1623 II
NCT02980692 · Phase 2 · registry result, not featured evidence
0.4487% (n=78) @ 20wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
0.4177% (n=79) @ 20wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
0.2857% (n=77) @ 20wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
0.2308% (n=78) @ 20wkDose IV then SUNPG1623 II
NCT02980692 · Phase 2 · registry result, not featured evidence
0.5256% (n=78) @ 24wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
0.5063% (n=79) @ 24wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
0.4545% (n=77) @ 24wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
0.3974% (n=78) @ 24wkDose IV then SUNPG1623 II
NCT02980692 · Phase 2 · registry result, not featured evidence
0.791% (n=78) @ 52wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
0.75% (n=79) @ 52wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
0.7213% (n=77) @ 52wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
0.68% (n=78) @ 52wkDose IV then SUNPG1623 II
NCT02980692 · Phase 2 · registry result, not featured evidence
ACR70 0% (n=78) @ 1wkI
responder rate · % of participants
No placebo or comparator arm
NCT02980692 · Phase 2 · registry result, not featured evidence
show 31 more results
0.0127% (n=79) @ 1wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
0% (n=77) @ 1wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
0% (n=78) @ 1wkDose IV then SUNPG1623 II
NCT02980692 · Phase 2 · registry result, not featured evidence
0.0128% (n=78) @ 4wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
0.0127% (n=79) @ 4wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
0% (n=77) @ 4wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
0.0128% (n=78) @ 4wkDose IV then SUNPG1623 II
NCT02980692 · Phase 2 · registry result, not featured evidence
0.0256% (n=78) @ 8wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
0.038% (n=79) @ 8wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
0.026% (n=77) @ 8wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
0.0256% (n=78) @ 8wkDose IV then SUNPG1623 II
NCT02980692 · Phase 2 · registry result, not featured evidence
0.1026% (n=78) @ 12wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
0.038% (n=79) @ 12wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
0.0649% (n=77) @ 12wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
0.1026% (n=78) @ 12wkDose IV then SUNPG1623 II
NCT02980692 · Phase 2 · registry result, not featured evidence
0.141% (n=78) @ 16wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
0.1266% (n=79) @ 16wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
0.1169% (n=77) @ 16wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
0.0897% (n=78) @ 16wkDose IV then SUNPG1623 II
NCT02980692 · Phase 2 · registry result, not featured evidence
0.2051% (n=78) @ 20wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
0.2658% (n=79) @ 20wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
0.1429% (n=77) @ 20wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
0.1282% (n=78) @ 20wkDose IV then SUNPG1623 II
NCT02980692 · Phase 2 · registry result, not featured evidence
0.2821% (n=78) @ 24wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
0.2911% (n=79) @ 24wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
0.2208% (n=77) @ 24wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
0.1667% (n=78) @ 24wkDose IV then SUNPG1623 II
NCT02980692 · Phase 2 · registry result, not featured evidence
0.5821% (n=78) @ 52wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
0.4844% (n=79) @ 52wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
0.3934% (n=77) @ 52wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
0.4% (n=78) @ 52wkDose IV then SUNPG1623 II
NCT02980692 · Phase 2 · registry result, not featured evidence
Tender Joint Count -1.5 vs -2.1 placebo count @ 1wkI
absolute change · count
NCT02980692 · Phase 2 · registry result, not featured evidence
show 27 more results
-2.4 vs -2.1 placebo count @ 1wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-2.5 vs -2.1 placebo count @ 1wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-3.1 vs -2.1 placebo count @ 1wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-4.7 vs -4.1 placebo count @ 4wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-4.9 vs -4.1 placebo count @ 4wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-5.4 vs -4.1 placebo count @ 4wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-3.9 vs -4.1 placebo count @ 4wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-7.1 vs -6.9 placebo count @ 8wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-7.8 vs -6.9 placebo count @ 8wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-8.6 vs -6.9 placebo count @ 8wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-7.2 vs -6.9 placebo count @ 8wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-8.3 vs -7.7 placebo count @ 12wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-10 vs -7.7 placebo count @ 12wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-8.7 vs -7.7 placebo count @ 12wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-7.8 vs -7.7 placebo count @ 12wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-10.3 vs -8.4 placebo count @ 16wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-11.3 vs -8.4 placebo count @ 16wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-10.7 vs -8.4 placebo count @ 16wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-9.8 vs -8.4 placebo count @ 16wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-11.2 vs -9.9 placebo count @ 20wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-12.3 vs -9.9 placebo count @ 20wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-11.5 vs -9.9 placebo count @ 20wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-11.4 vs -9.9 placebo count @ 20wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-11.9 vs -9.4 placebo count @ 24wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-12.6 vs -9.4 placebo count @ 24wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-12.9 vs -9.4 placebo count @ 24wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-12 vs -9.4 placebo count @ 24wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
Tender Joint Count -12.3 count @ 52wkI
absolute change · count
No placebo or comparator arm
NCT02980692 · Phase 2 · registry result, not featured evidence
show 3 more results
-13.7 count @ 52wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-16 count @ 52wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-14 count @ 52wkDose IV then SUNPG1623 II
NCT02980692 · Phase 2 · registry result, not featured evidence
Swollen Joint Count -1.8 vs -1.3 placebo count @ 1wkI
absolute change · count
NCT02980692 · Phase 2 · registry result, not featured evidence
show 27 more results
-2.1 vs -1.3 placebo count @ 1wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-1.3 vs -1.3 placebo count @ 1wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-2.4 vs -1.3 placebo count @ 1wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-4.1 vs -3.1 placebo count @ 4wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-3.8 vs -3.1 placebo count @ 4wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-3.8 vs -3.1 placebo count @ 4wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-3 vs -3.1 placebo count @ 4wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-5.8 vs -4.7 placebo count @ 8wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-5.5 vs -4.7 placebo count @ 8wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-5.7 vs -4.7 placebo count @ 8wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-5 vs -4.7 placebo count @ 8wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-7.3 vs -4.9 placebo count @ 12wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-6.6 vs -4.9 placebo count @ 12wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-6.2 vs -4.9 placebo count @ 12wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-4.8 vs -4.9 placebo count @ 12wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-8 vs -5.2 placebo count @ 16wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-7.2 vs -5.2 placebo count @ 16wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-7 vs -5.2 placebo count @ 16wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-6 vs -5.2 placebo count @ 16wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-8.3 vs -6 placebo count @ 20wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-7.4 vs -6 placebo count @ 20wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-7.4 vs -6 placebo count @ 20wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-6.8 vs -6 placebo count @ 20wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-8.3 vs -6.5 placebo count @ 24wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-7.7 vs -6.5 placebo count @ 24wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-8.2 vs -6.5 placebo count @ 24wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-7.6 vs -6.5 placebo count @ 24wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
Swollen Joint Count -8.7 count @ 52wkI
absolute change · count
No placebo or comparator arm
NCT02980692 · Phase 2 · registry result, not featured evidence
show 3 more results
-7.5 count @ 52wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-9.2 count @ 52wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-7.5 count @ 52wkDose IV then SUNPG1623 II
NCT02980692 · Phase 2 · registry result, not featured evidence
Physician Global Assessment -7.8 vs -4.5 placebo score @ 1wkI
absolute value · score
NCT02980692 · Phase 2 · registry result, not featured evidence
show 27 more results
-8 vs -4.5 placebo score @ 1wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-7.2 vs -4.5 placebo score @ 1wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-6.2 vs -4.5 placebo score @ 1wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-14.3 vs -9.7 placebo score @ 4wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-15.7 vs -9.7 placebo score @ 4wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-15.1 vs -9.7 placebo score @ 4wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-14 vs -9.7 placebo score @ 4wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-21.9 vs -16.2 placebo score @ 8wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-23.6 vs -16.2 placebo score @ 8wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-23.9 vs -16.2 placebo score @ 8wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-20.8 vs -16.2 placebo score @ 8wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-27.9 vs -18.5 placebo score @ 12wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-28.7 vs -18.5 placebo score @ 12wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-27.6 vs -18.5 placebo score @ 12wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-23.1 vs -18.5 placebo score @ 12wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-31 vs -20.2 placebo score @ 16wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-32.1 vs -20.2 placebo score @ 16wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-31.7 vs -20.2 placebo score @ 16wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-30.8 vs -20.2 placebo score @ 16wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-36.7 vs -24.3 placebo score @ 20wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-36.8 vs -24.3 placebo score @ 20wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-31 vs -24.3 placebo score @ 20wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-33 vs -24.3 placebo score @ 20wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-36.5 vs -23.5 placebo score @ 24wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-38.8 vs -23.5 placebo score @ 24wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-37.5 vs -23.5 placebo score @ 24wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-36.3 vs -23.5 placebo score @ 24wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
Physician Global Assessment -40 score @ 52wkI
absolute change · score
No placebo or comparator arm
NCT02980692 · Phase 2 · registry result, not featured evidence
show 3 more results
-44.3 score @ 52wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-45.3 score @ 52wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-42.7 score @ 52wkDose IV then SUNPG1623 II
NCT02980692 · Phase 2 · registry result, not featured evidence
Patient Global Assessment -5.9 vs -2.8 placebo score @ 1wkI
absolute value · score
NCT02980692 · Phase 2 · registry result, not featured evidence
show 27 more results
-7.5 vs -2.8 placebo score @ 1wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-6.8 vs -2.8 placebo score @ 1wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-6.4 vs -2.8 placebo score @ 1wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-7.5 vs -5.9 placebo score @ 4wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-11.9 vs -5.9 placebo score @ 4wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-9.5 vs -5.9 placebo score @ 4wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-8.8 vs -5.9 placebo score @ 4wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-15.4 vs -10.1 placebo score @ 8wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-15.5 vs -10.1 placebo score @ 8wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-14.5 vs -10.1 placebo score @ 8wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-13.1 vs -10.1 placebo score @ 8wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-18.1 vs -11.2 placebo score @ 12wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-20.3 vs -11.2 placebo score @ 12wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-16.1 vs -11.2 placebo score @ 12wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-16.4 vs -11.2 placebo score @ 12wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-23.5 vs -13.8 placebo score @ 16wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-22 vs -13.8 placebo score @ 16wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-18.7 vs -13.8 placebo score @ 16wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-19.4 vs -13.8 placebo score @ 16wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-29.7 vs -15.6 placebo score @ 20wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-27.3 vs -15.6 placebo score @ 20wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-22.7 vs -15.6 placebo score @ 20wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-21.6 vs -15.6 placebo score @ 20wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-35 vs -21.7 placebo score @ 24wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-33.3 vs -21.7 placebo score @ 24wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-33.4 vs -21.7 placebo score @ 24wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-30.4 vs -21.7 placebo score @ 24wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
Patient Global Assessment -42.2 score @ 52wkI
absolute change · score
No placebo or comparator arm
NCT02980692 · Phase 2 · registry result, not featured evidence
show 3 more results
-43.8 score @ 52wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-38.4 score @ 52wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-37.9 score @ 52wkDose IV then SUNPG1623 II
NCT02980692 · Phase 2 · registry result, not featured evidence
Patient Pain VAS -5.8 vs -1.6 placebo score @ 1wkI
absolute value · score
NCT02980692 · Phase 2 · registry result, not featured evidence
show 27 more results
-8.1 vs -1.6 placebo score @ 1wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-5.1 vs -1.6 placebo score @ 1wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-5.8 vs -1.6 placebo score @ 1wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-9.8 vs -3.9 placebo score @ 4wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-12.8 vs -3.9 placebo score @ 4wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-8.9 vs -3.9 placebo score @ 4wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-6.4 vs -3.9 placebo score @ 4wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-16.9 vs -8.5 placebo score @ 8wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-16.1 vs -8.5 placebo score @ 8wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-16.6 vs -8.5 placebo score @ 8wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-11.9 vs -8.5 placebo score @ 8wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-19.4 vs -11.5 placebo score @ 12wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-20.4 vs -11.5 placebo score @ 12wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-15.6 vs -11.5 placebo score @ 12wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-14 vs -11.5 placebo score @ 12wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-23.8 vs -12.8 placebo score @ 16wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-23.2 vs -12.8 placebo score @ 16wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-20.6 vs -12.8 placebo score @ 16wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-19.3 vs -12.8 placebo score @ 16wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-29.8 vs -17.1 placebo score @ 20wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-25.3 vs -17.1 placebo score @ 20wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-21.4 vs -17.1 placebo score @ 20wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-21.4 vs -17.1 placebo score @ 20wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
-35.1 vs -21.5 placebo score @ 24wkI
NCT02980692 · Phase 2 · registry result, not featured evidence
-31.6 vs -21.5 placebo score @ 24wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-32.1 vs -21.5 placebo score @ 24wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-28.8 vs -21.5 placebo score @ 24wkDose IV
NCT02980692 · Phase 2 · registry result, not featured evidence
Pain VAS -40.7 score @ 52wkI
absolute change · score
No placebo or comparator arm
NCT02980692 · Phase 2 · registry result, not featured evidence
show 3 more results
-42.7 score @ 52wkII
NCT02980692 · Phase 2 · registry result, not featured evidence
-38 score @ 52wkDose III
NCT02980692 · Phase 2 · registry result, not featured evidence
-37.6 score @ 52wkDose IV then SUNPG1623 II
NCT02980692 · Phase 2 · registry result, not featured evidence

+ 7 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: risankizumab's landscape · tildrakizumab's landscape